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N6-methyladenosine (m6A) is the most abundant modified nucleotide occurring in 
mRNA, with key roles in RNA metabolism and regulation of gene expression. Proposed 
effects of m6A modification of RNA transcripts include effects on transcript half-life, 
translation efficiency, splicing and miRNA biogenesis. Importantly, m6A is the only 
known dynamic RNA modification, with deposition mediated by the “writer” METTL3, 
and demethylation carried out by the “erasers” ALKBH5 and FTO. We hypothesized a 
role for m6A in hematopoiesis, with potential disease relevance in myeloid malignancies. 
To gain an understanding of the effects of m6A on normal hematopoiesis and 
myeloid malignancies such as the myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML), we developed conditional knockout mice for the m6A writer METTL3, 
and the eraser ALKBH5. We find that deletion of METTL3 results in embryonic 
lethality, with an accumulation of dysfunctional hematopoietic stem cells (HSCs) that are 
incompetent in hematopoietic rescue assays. We further characterize disturbances in 
myeloid & lymphoid lineage differentiation. Deletion of ALKBH5 does not result in 
steady-state hematopoietic dysfunction, but results in hematopoietic stem cell 
deficiencies in competitive transplant assays.     
We propose that deletion of METTL3 locks HSCs in a naïve multipotent state, 
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The Myelodysplastic Syndromes 
The myelodysplastic syndromes (MDS) encompass a variety of disorders 
characterized by clonal hematopoiesis and differentiation defects in the myeloid lineage. 
Clonal hematopoiesis refers broadly to the outgrowth of a single hematopoietic stem cell 
(HSC) and its progeny as a consequence of a competitive growth advantage endowed by 
disease-causing mutations. The advantaged stem cell clone displaces the remaining 
normal HSCs, while giving rise to abnormal myeloid precursors which cannot 
successfully navigate myeloid differentiation. This results in an accumulation of stalled, 
immature myeloid “blasts” in the bone marrow, with a scarcity of mature myeloid cells in 
the peripheral blood1–3. Clinically, insufficient numbers of erythrocytes produce anemia 
& fatigue, decreased numbers of leukocytes result in immunocompromise & infection, 
and depleted or dysfunctional platelet reserves coincide with easy bruising and 
hemorrhage.   
The number of lineages affected by peripheral blood cytopenias, as well as the 
frequency of myeloid blasts in the bone marrow form the basis of the WHO clinical 
classification of MDS. The various subtypes of MDS reflect a spectrum of disease 
ranging from mild cytopenias to overt acute myeloid leukemia (AML). Refractory 
cytopenias with unileage dysplasia or multilineage dysplasia (RCUD, RCMD) are both 
characterized by fewer than 5% blasts in the bone marrow, while refractory anemia with 
excess blasts (RAEB I & II) encompasses two subtypes of increasing severity, with 5-9% 
marrow blasts and 10-19% marrow blasts, respectively. Additional subtypes are specified 
by hallmark features, such as the presence of ringed sideroblasts (refractory anemia with 
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ringed sideroblasts; RARS), monocytosis (chronic myelomonocytic leukemia; CMML), 
or association with genetic deletion of 5q (MDS with isolated 5q-). prevention of 
hematologic neoplasms or early disease therapy2,4.   
Of note, MDS is a disease of older patients, with a median age at diagnosis of 71 
years. Disease morbidity and mortality are high 4,5, and therapeutic options are limited. 
Typically, patients with MDS are managed based on the number and severity of 
peripheral blood cytopenias. Patients with low risk disease or favorable prognosis can 
continue with a regimen of supportive care including transfusions, antibiotics, and growth 
factor replacement with erythropoietin or granulocyte-stimulating factors. Select patients 
may respond to immunomodulatory therapy with antithymocyte globulin, thalidomide or 
lenalidomide6. Patients with presence of the chromosomal lesion del(5q) are similarly 
responsive to lenalidomide6,7.  For patients with high risk disease, DNA hypomethyalting 
agents such as decitabine or 5-azacitidine are used, though their mechanism of action is 
poorly understood. Though azacitidine prolonged survival by several months in clinical 
trials, overall survival remained poor at approximately 2 years8,9. Treatment with 
decitabine produces similarly modest results10. Allogeneic stem cell transplant remains 
the only curative option for MDS, but its use has been limited to young patients with 
higher risk disease11.  
Though these therapies are useful and important tools in the face of a 
tremendously poor outcomes, they do little to specifically target disease pathogenesis, 
and the basic mechanisms underlying MDS remain incompletely understood. Insights 
into the genetic lesions and consequent altered cellular processes in MDS have been of 
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particular interest, as they could serve as prognostic markers of disease, and potential 
therapeutic targets.        
The Spectrum of Clonal Hematopoiesis 
Importantly, MDS exists as one of a broad spectrum of clonal disorders affecting 
the myeloid lineage which share common underlying pathophysiology and mutations. On 
the more severe end of this spectrum lie the acute myeloid leukemias (AML). 
Approximately one third of patients with MDS will have their disease progress to a 
‘secondary’ acute myeloid leukemia (sAML). By clinical criteria, patients are considered 
to have progressed when the frequency of bone marrow blasts exceeds 20%1,2. While this 
threshold is somewhat arbitrary, increasing blast percentage in the bone marrow 
coincides with their emergence in the peripheral blood. As immature blasts flood the 
peripheral blood, the transformation to leukemia is reflected in laboratory testing by an 
increasing leukocyte count on laboratory testing. While AML may arise secondary to 
MDS as described, the majority of AML arises de novo, without any apparent precursor 
condition. The disease-causing mutations occurring in de novo AML overlap with those 
observed in sAML, but their distribution diverges significantly a subset of mutations 
diverge significantly. Splicing factor mutations, for instance, tend to occur preferentially 
in sAML, while NPM1 mutations are characteristic of de novo AML12. This suggests 
some distinction in the disease mechanisms of these two conditions.  
While acute leukemias reflect the most aggressive end of the spectrum of clonal 
hematopoiesis, a ‘clinically-silent’ variant termed clonal hematopoiesis of indeterminate 
potential (CHIP) has also recently been described13. The discovery of this condition was 
driven by the hypothesized existence of a precursor condition to both MDS & AML that 
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might be detected in healthy individuals. In theory the accumulation of only one or two 
disease-causing mutations in a hematopoietic stem cell would provide it with a 
competitive growth advantage over neighboring HSCs. This would result in an expansion 
of the mutant clone, without manifesting as overt malignancy. Over time, the 
accumulation of additional mutations in these pre-malignant HSC clones might lead to 
the development of overt MDS or AML. Importantly, this hypothesized period of benign 
clonal hematopoiesis in healthy individuals would provide a window of time during 
which early hematopoietic neoplasia could be detected and eradicated prior to the 
development of malignancy.  
The existence of such a condition was recently substantiated by deep sequencing 
of peripheral blood samples from large observational trial cohorts14,15. While none of the 
individuals in these trials had any known hematopoietic disease, sequencing revealed 
low-frequency accumulation of mutations associated with MDS & AML in 10-20% of 
the study population. These individuals typically carried only one or two MDS mutations, 
with expansion of the hematopoietic clone inferred from increased mutant allele 
frequency14. This observation has formed the basis for a working formal definition of 
CHIP – patients with CHIP must have somatic clonal mutations affecting genes 
associated with hematologic malignancy in the absence of any clinical or laboratory 
evidence hematologic malignancy, with a mutant allele frequency exceeding 2% in the 
peripheral blood12. Like MDS and AML, CHIP tends to occur in older individuals, 
reflecting the increasing stochastic mutation burden with age. Nevertheless, there are also 
individuals with CHIP as young as 40 years of age14,15. The extent to which CHIP fulfills 
the role of hypothesized precursor condition to MDS or AML is somewhat limited. In 
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general, few cases of CHIP transition to MDS or other hemaopoietic malignancies, 
totaling only 0.5-1% risk of progression per year14. As a result, though CHIP exists along 
the same spectrum of myeloid disease pathophysiology as MDS and sAML, it is 
exceedingly more likely that CHIP will occur as a standalone condition in elderly 
individuals without progressing.  
With this in mind, study has turned towards other possible non-malignant, chronic 
effects of this condition. Surprisingly, CHIP has been tied to increased mortality related 
to atherosclerotic coronary artery disease, with dysfunctional granulocytes and 
macrophages proposed to contribute to enhanced inflammation and atherosclerotic plaque 
formation15. This altogether unexpected finding ties the realm of hematologic neoplasm 
to cardiovascular mortality. 
While these studies have successfully identified a new disease entity with 
unexpected clinical outcomes, the limited progression of CHIP to MDS or AML suggest 
that CHIP is unfortunately not likely to be a meaningful point of intervention for broad 
prevention of hematopoietic malignancy. As a result, the study of disease mechanisms in 
MDS remains an important endeavor towards developing therapies and minimizing the 
disease burden of myeloid malignancies.  
Disease Mutations in MDS 
Recent efforts to characterize MDS have focused on deep sequencing and 
mutation discovery. Sequencing cohorts of MDS patients has led to the identification of 
recurrent mutations in genes involved in epigenetic regulation (TET2, IDH1/2, 
DNMT3A, ASXL1, EZH2), signal-transduction (JAK2, MPL), the RAS & p53 pathways, 
cohesin complexes, known hematopoietic transcription factors (ETV6, RUNX1, GATA2) 
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and the RNA Splicing machinery1,16,17. Mutations in splicing machinery proteins – 
primarily SF3B1, U2AF1 and SRSF2 – occur in 65% of MDS cases overall, and 25% of 
sAML cases17. Notably, mutations in individual splice factors are mutually exclusive. 
Taken together, these findings imply either that these mutations funnel into a common 
disease phenotype, or that mutations in two or more spliceosome components are lethal16. 
Mutations resulting in altered epigenetic regulation include those occurring in 
IDH1, IDH2, and Tet218. Mutations in IDH1/2 occur in 5-20% transformed% of patients 
with MDS and up to 30% of patients with de novo and secondary AML19,20. Cytosolic 
IDH1 and its mitochondrial counterpart IDH2 are responsible for the conversion of 
isocitrate to 2-α-ketoglutarate (α-KG) in the context of cellular metabolism. Mutations in 
residue R132 of IDH1, and R140 or R172 in IDH2 endow these enzymes with a 
neomorphic function, resulting in the conversion of α-KG to D-2-hydroxyglutarate (2-
HG)21–23. In addition to its role as an intermediate in the citric acid cycle, α-KG is a 
required metabolite for the function of the α-KG-dependent dioxygenase family of 
enzymes. Owing to its close molecular resemblance to α-KG, 2-HG acts as a competitive 
inhibitor of α-KG-dependent enzymes.  
Interestingly, Tet2 is an α-KG-dependent dioxygenases. Tet2 mutations are 
furthermore mutually exclusive with IDH1/2 mutations, implying a common function. 
Indeed, consistent with the hypothesized mechanism of action of 2-HG, Tet2 is inhibited 
in the context of IDH1/2 mutations, resulting in a DNA hyper-methylation phenotype 
resembling the phenotype of Tet2-mutant malignancies20. This suggests that alered 5-mC 
deposition is a common feature of IDH1/2 and Tet2 mutations that may have special 
relevance for malignancy. 
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Since the elucidation of this basic mechanism, several additional α-KG dependent 
dioxygenases have been implicated downstream of IDH1/2. These have included the Jmj 
family of histone demethylases24, and the DNA demethylases ALKBH2 & ALKBH325, 
which are involved in DNA repair. These enzymes have been proposed to play a role in 
disease pathogenesis and are relevant to therapeutic vulnerabilities in IDH1/2 mutant 
cancers.   
The Epitranscriptome: N-6-methyladenosine 
 For many decades, RNA bases have been known to carry various modifications. 
The N-6-methyladenosine (m6A) mark is the most abundant mRNA modification and 
was among the first to be described26. Though m6A was identified in RNA decades ago, 
study of this modification was limited for many years. For one, technical limitations 
made it difficult to extensively characterize. Detection of the modified ribonucleoside 
initially depended on liquid chromatography, which limited study to a handful of 
transcripts at a time. In addition, though a methyltransferase “writer” protein depositing 
m6A had been discovered and characterized, the absence of a demethylase or “eraser” 
protein suggested that the modification was static once deposited. This led to the 
assumption that m6A was unlikely to participate dynamically in regulation of gene 
expression. 
Ultimately this assumption was overturned with the recent discovery that the fat 
mass and obesity-associated protein (FTO) catalyzes the demethylation of m6A 27. This 
was followed shortly by the discovery of a second demethylase, ALKBH5 28. 
Interestingly, both demethylases are α-KG dependent dioxygenases. The discovery of 
demethylases introduced the possibility that physiologic gene regulation might be 
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mediated by m6A at the level of the transcript, a concept that reinvigorated interest in the 
possibility of a dynamic “epitranscriptome”. Simultaneously, technical advances made it 
possible to study the transcriptome-wide distribution of m6A. Using an antibody specific 
for the modified m6A nucleotide, RNA transcripts containing could be selectively 
immune-precipitated and fragmented prior to RNA sequencing, with the location of 
modified m6A modified bases inferred from the sequencing peaks. This process, termed 
m6A-seq or methylated RNA immunoprecipitation and sequencing (meRIP-seq) by 
independent groups29–31, provided the first insights into the distribution and function of 
m6A nucleotides.  
The Epitranscriptome Map 
The first two transcriptome-wide maps of m6A were published within months of 
each other with largely convergent results29,30. In both cases, human and murine tissues 
were subjected to m6A seq, with ~13,000 m6A peaks identified within ~8,000 gene 
coding transcripts and several hundred non-coding transcripts. Overall, 95% of m6A sites 
was intragenic. The observed m6A peaks conformed to the expected RRAC (R = purine) 
consensus motif, which is identical to the binding motif of the previously identified m6A 
methyltransferase METTL3. In both studies, the distribution of m6A across the 
transcription start site (TSS), 5’UTR, coding sequence (CDS), and 3’UTR was examined. 
The most prominent feature of the m6A distribution was its heavy enrichment in 
the 3’UTR near the stop codon. The 3’UTR and region adjacent to the stop codon 
accounted for over a quarter of all m6A residues, representing a greater than two-fold 
enrichment when normalized for length, and one third of all genes contained an m6A site 
in these regions.  
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While the TSS was also relatively enriched for m6A, many of these sites did not 
conform to the expected consensus sequence, leading to the conclusion that these sites 
were likely false positives owing to antibody recognition of the similar (N6-,2’-O)-
dimethyladenosine (m6Am) modified nucleotide. The first base nucleotide downstream of 
the 5’ m7G cap of mRNA undergoes constitutive 2’-hydroxymethylation of the 
nucleotide ribose – as a result, when the first incorporated nucleotide is m6A, m6Am  
results. Several subsequent studies confirmed that the enrichment of ‘m6A’ in the 5’UTR 
is, in fact, attributable to m6Am
32–34.  
The CDS contained the most m6A peaks of any region, but was relatively under-
enriched when normalized for length. There was a strong tendency for increasing m6A 
deposition towards the 3’end of the CDS29,30.  
Beyond mapping the distribution of m6A, both groups provided evidence towards 
its potential function.  
To show that m6A might be dynamically modified, m6A-seq was performed on 
human hepatocellular carcinoma cell lines under a series of stress conditions including 
UV light, heat shock, growth factor & interferon signaling. While 70-95% of peaks were 
conserved across all conditions, a subset of m6A sites were altered in each case 
suggesting physiologic adaptability under stress conditions30.  
Using computational algorithms to identify RNA regulatory elements associated 
with the m6A motif, one group showed that m6A motifs overlap with miRNA binding 




Both groups explored the possibility of m6A mediated splicing, but reached 
opposing conclusions. While knockdown of METTL3 appeared to produce differential 
splicing in hepatocellular carcinoma cell lines30, computational motif recognition of m6A 
sites did not find any significant enrichment at exon-exon junctions, which would 
presumably be required for differential splicing factor recruitment.  
Lastly, to identify mediators of downstream effects of the m6A modification, one 
of the groups used RNA affinity chromatography with and m6A-containing bait transcript 
to identify the first known “readers” of m6A including the YTH family proteins 
YTHDF1, 2 & 3.  
These findings provided the first evidence for a dynamic epitranscriptome 
mediating transcript-level regulation of gene expression. Since the publication of these 
landmark studies, an abundant literature has emerged characterizing the role of m6A in 
molecular, cellular and organismal processes. This has coincided with an expansion of 
the known repertoire of m6A interacting proteins. In addition to the aforementioned 
erasers (FTO & ALKBH5), new components of the methyltransferase complex 
(METTL3, METTL14, WTAP, RBM15) and several novel m6A “readers” (YTHDF1, 
YTHDF2 YTHDC1, eIF3, hnRNPA2B1, HUR) have been identified. As this literature 
has evolved, many of the initially hypothesized roles for m6A and its interacting proteins 
have been further revised or contextualized.  
Here, I will provide a brief review of the emerging m6A literature, provide the 
rationale for a hypothesized role of m6A in hematopoiesis in myelodysplasia, and discuss 
some of the recent evidence supporting a role for m6A in human malignancy.  
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Hypothesized Role of m6A in Hematopoiesis 
The possibility of a role for the m6A machinery in hematopoiesis is compelling. 
Both known erasers of the m6A mark – FTO and ALKBH5 – are members of the family 
of α-KG-dependent dioxygenases27,28. The α-KG-dependent dioxygenases have 
previously been implicated in the pathogenesis of IDH1/2-mutated MDS & leukemia, as 
discussed above. It is possible that IDH mutations lead to a similar, 2-HG mediated 
inhibition of the α-KG-dependent dioxygenases. While this observation formed the initial 
basis for our interest in m6A during hematopoiesis, in the time since we have initiated our 
own studies, several studies have been published demonstrating the relevance of m6A to 
the pathogenesis of IDH1/2 mutant AML35–37. Elsewhere, several groups have observed 
that METTL3 is overexpressed in AML in comparison to normal hematopoietic cells38–40. 
Lastly, RBM15 (also known as OTT1), a component of the methyltransferase complex 
that guides it to specific target sequences41, is a component of the fusion oncogene OTT-
MKL, which occurs in acute megakaryoblastic leukemia42. These findings will discussed 
further below.   
Technical Advances in the Detection of m6A 
 Since the development of the initial m6A-seq protocol, several improvements on 
the technique have been made. The m6A-seq protocol relies on fragmentation of RNA to 
~100-200 nucleotide fragments, followed by immunoprecipitation of the modified RNAs 
with an m6A-specific antibody. The m6A-enriched RNA is then competitively eluted 
from the antibody, followed by cDNA synthesis and traditional high-throughput 
sequencing. The major limitation of this technique is the level of resolution – because of 
the size of the input RNA fragments, the sequencing reads inevitably form a broad peak 
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flanking the isolated m6A site. Because of the relative frequency of the RRAC motif, 
which could occur every 64 nucleotides, a single sequencing peak can encompass more 
than one consensus motif31. This would preclude identification of the precise location of 
an m6A site. Furthermore, this would preclude identification of modified adenosines 
occurring outside the pre-determined consensus motif.  
Improved resolution of m6A identification has been achieved by combining m6A-
specific immunoprecipitation with crosslinking and immunoprecipitation (CLIP), a well-
established technique typically used to identify the target sites of RNA-binding proteins. 
In traditional CLIP, protein crosslinking to bound RNA is induced via UV 
irradiation. The protein of interest is then immunoprecipitated, and then the bound RNA 
is digested to ~30-70nt fragments labeled with radioactive Phosphorus-32 (P32), and 
tagged with sequencing adapters. Radioactive protein-RNA complexes are then isolated 
by SDS-PAGE electrophoresis, and the bound protein is removed by Proteinase K 
digestion. The isolated RNA can then be reverse transcribed to cDNA, which is 
submitted for high-throughput sequencing. Binding sites can be inferred from the 
resulting distribution of sequencing peaks, as would be possible in m6A-seq. Howe, 
crosslinking also produces artefacts in the sequencing data which identify the 
crosslinking site at single-nucleotide resolution. UV irradiation leads to hallmark 
crosslink-induced mutation sites (CIMS). Reverse transcription is also often prematurely 
truncated by a residual polypeptide fragment attached to the RNA following proteinase K 
digestion, which result in the formation of crosslink-induced truncation sites (CITS)43. 
An improved variant of CLIP termed termed individual-nucleotide CLIP (iCLIP) relies 
on the circularization of cDNA products to position CITS directly downstream of a 
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transcript-specific barcode sequence. These circularized cDNAs is then linearized by 
cleavage at a specific restriction enzyme digest site, and sequenced, allowing for 
identification of CITS at the first nucleotide position downstream of the crosslink site44. 
Ultimately these characteristic alterations can be detected computationally, and 
assembled into reliable RNA-binding maps.     
Performing m6A-directed iCLIP (miCLIP) is accomplished relatively simply by 
preforming the iCLIP on RNA incubated with an m6A-specific antibody. In this instance, 
UV irradiation crosslinks the m6A antibody directly to modified nucleotides prior to 
immunoprecipitation, allowing precise m6A localization. Minor variations of this 
procedure were published within months of each other33,45. The initial characterization of 
miCLIP demonstrated that it reliably identified validated m6A modification sites, 
including m6Am nucleotides in the 5’UTR. Furthermore, miCLIP identified m
6A on small 
RNAs such as snoRNAs, which are normally too small to allow reliable m6A 
identification33. The Darnell group made the further observation that reverse transcription 
across m6A immunoprecipitated RNAs without crosslinking could also lead to premature 
truncation. By comparing the cDNA sequence derived from input RNA with cDNA 
derived from m6A-IP samples, m6A-induced truncation sites (MITS) could also be 
identified. They termed this combined procedure m6A-CLIP/IP, and used it to identify 
m6A sites with high confidence45.  
Importantly, these techniques resolved existing ambiguities in the 
epitranscriptome map. Performing m6A-CLIP/IP confirmed the enrichment of m6A in the 
3’UTR, with over 70% of m6A nucleotides found in this region. However, the enrichment 
of m6A near the stop codon was clarified45. CLIP directed against m6A showed that m6A 
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decreases gradually towards the 3’ end of the CDS and peaks rapidly within the first 150-
400 nucleotides of the last exon. Though this region tends to be closely associated with 
the stop codon, the precise placement of m6A nucleotides within the 3’UTR was agnostic 
to the position of the stop codon. Rather, it appears that m6A is preferentially found in the 
last exon. This finding was confirmed by examining a subset of RNAs which have a non-
coding last exon downstream of a stop codon in a preceding exon. In these cases, m6A 
methylation continued to be enriched in the last exon, without enriched methylation near 
the upstream stop codon. 45. These increasingly specific findings reflect the value of 
enhanced resolution with m6A-CLIP/IP & miCLIP.  
To this point miCLIP represents the tool of choice for transcriptome-wide m6A 
mapping. While this represents a tremendous advance, the protocol intrinsically depends 
on the specificity of the antibody, efficiency of immunoprecipitation and crosslinking, 
which are likely imperfect. Alternative methods have been used to sequence other 
modified nucleotides. The DNA & RNA modification 5-methylcytosine (5-mC) is 
identified by treatment with bisulfite, which induces characteristic mutations of 5-mC to 
uracil. The DNA modification N6-methyladenine (N6-mA) is identifiable by 
characteristic slowing of DNA Polymerase during sequencing. To date, m6A has proved 
resistant to chemical modification, and produces no detectable sequencing artefacts. In 






Molecular Roles of m6A: Integration of RNA Metabolism 
 With the technical advances in transcriptome-wide detection of m6A, there has 
been tremendous interest in its effects on RNA metabolism. Proposed roles thus far have 
included effects on transcript stability, translation efficiency, alternative splicing, 
polyadenylation, and recruitment of RNA binding proteins. In the subsequent sections I 
will discuss the effects of m6A RNA biology at the molecular and cellular levels.     
Timing of m6A Deposition and the “Dynamic” m6A Methylome  
Multiple studies provide strong evidence that m6A is deposited co-
transcriptionally. One of the most rigorous relied on cell fractionation techniques to 
specifically isolate chromatin-associated RNA (CA-RNA), nucleoplasmic RNA and 
cytoplasmic RNA. CA-RNA is composed predominantly of nascent pre-mRNA 
transcripts, which are partially spliced. By the time these transcripts reach the 
nucleoplasm, transcripts are fully spliced, and are finally trafficked into the cytoplasm. 
Performing miCLIP on these fractions in HeLa cells revealed that 90% of m6A peaks are 
identical between CA-RNA and nucleoplasmic RNA, while over 99% are identical 
between nucleoplasmic and cytoplasmic RNA46. These results provide strong evidence 
that the overwhelming majority of m6A must be deposited co-transcriptionally. Of note, 
the minor differences between nucleoplasmic and cytoplasmic RNA methylation also call 
into doubt the extent to which the predominantly nuclear m6A erasers FTO and 
ALKBH5 perform meaningful RNA demethylation in steady-state conditions47.  
Additional evidence for co-transcriptional RNA modification comes from the 
detection of METTL3 bound to chromatin-associated nascent RNA transcripts. In 
modified chromatin immunoprecipitation (ChIP) experiments, METTL3 bound to 
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elongating RNA transcripts can be detected by long-range chemical crosslinking of 
proteins to the associated DNA upon treatment with disuccinimidyl glutarate. This 
procedure demonstrated that the methyltransferase complex is bound to nascent RNA in 
close association with chromatin throughout the genome, in a distribution reminiscent of 
the known m6A methylome. Performing ChIP against METTL3 during heat shock further 
revealed a global reduction in METTL3 binding with specific re-localization to heat 
shock genes48. In another study, traditional ChIP directed against METTL3 in AML cell 
lines demonstrated that METTL3 can also be recruited to the promoters of genes whose 
transcripts are subsequently m6A-modified38.   
Together these findings support early deposition of m6A during transcription. The 
consistent m6A distribution across nuclear and cytoplasmic RNAs strongly suggests that 
the RNA demethylases FTO & ALKBH5 may not exert a significant influence on steady-
state RNA metabolism. However, this finding needn’t imply that m6A cannot be 
‘dynamically’ modified. The redistribution of METTL3 upon heat shock implies a 
distinct mechanism of inducing global shifts in m6A profile48. Similarly, experimental 
modulation of FTO expression during heat-shock suggests its important regulatory 
function in stress-response49. The m6A readers, writers, or erasers may be similarly 
induced during stress conditions, cellular signaling, or developmental events to remodel 




Effects of m6A on Transcript Stability & Translation Efficiency 
 The effects of m6A on RNA metabolism following transcription has been 
investigated at the level of transcript stability and translation efficiency using a 
straightforward set of molecular techniques.  
Transcript abundance is readily determined by traditional RNA-sequencing, 
while m6A modified transcripts may be identified via miCLIP.  
The half-life of transcripts can be assessed by RNA sequencing at multiple time 
points following treatment with the transcription inhibitor actinomycin D. In theory, with 
no new transcripts entering the cellular pool of RNA, transcript decay can be measured in 
this manner. This procedure has been termed RNA lifetime profiling.  
Lastly, effects of m6A modification on ribosomal loading and efficiency of 
translation can be determined by ribosome profiling (also known as ribo-seq, or 
ribosome footprinting). In this technique, ribosomes are locked in place on actively 
translated mRNAs by treatment with the translation inhibitor cycloheximide. 
Ribonuclease treatment degrades exposed mRNA, while the immobilized ribosomes 
protect their bound mRNA fragments. The ribosome-bound mRNAs can then be isolated 
using size-specific protein isolation techniques such as sucrose gradients. The intact 
mRNAs are then dissociated from the ribosomes and can then be subjected to traditional 
RNA sequencing50. The quantity of sequencing reads provides a measure of ribosome 
occupancy for a given transcript, which is used as a surrogate measure of net translation. 
The ‘translational efficiency’ of any given transcript can then be determined as a ratio of 
ribosome occupancy (reads per million by ribo-seq) to transcript abundance (reads per 
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million by RNA-seq)51. Several publications have leveraged these techniques to explore 
m6A-mediated regulation of transcript decay and translation.   
The effects of m6A on transcript stability and turnover were first elucidated by 
knock-down experiments examining the function of the m6A reader YTHDF252. RNA-
seq and half-life profiling performed in YTHDF2 knock-down cell lines showed an 
increase in the abundance and half-life of m6A-modified transcripts that were also known 
targets of YTHDF2. Ribosome profiling, however, showed no change in the amount of 
ribosome-bound mRNA in the knock-down condition. Together, these findings suggest 
that in the absence of YTHDF2, there must be an increase in non-ribosome mRNA in the 
cells. This implies that YTHDF2 promoting the degradation of m6A-modified transcripts 
under normal conditions. Indeed, YTHDF2 was found to be necessary for targeting m6A-
modified transcripts to processing bodies (P bodies), which are cytoplasmic protein-RNA 
complexes responsible for mRNA degradation52. While these findings provided a clear 
mechanism for YTHDF2-mediated degradation of m6A-modified transcripts, it is 
important to note that these experiments focused solely on the role of YTHDF2 in m6A 
metabolism. The overall effect of m6A on transcript metabolism, however, depends on 
the integrated effects of multiple m6A readers. The net effect of m6A is therefore better 
assessed by knocking out the methyltransferase METTL3.  
Many of the early studies on METTL3 knockdown53,54 and knockout51,55 cells 
were performed on murine embryonic stem cells (mESCs). The most detailed of these 
examined the effects of METTL3 knockout on the early transition of mESCs from an 
early “naïve” state favoring self-renewal, to a “primed” state favoring differentiation 
referred to as epiblast stem cells51. In a molecular screen, METTL3 knockdown resulted 
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in destabilization of primed epiblast stem cells, favoring the naïve state instead. METTL3 
knockout mESCs were found to be correspondingly deficient in hallmark assays of tri-
lineage differentiation, but maintained enhanced self-renewal activity even after recovery 
from long-term culture in differentiation media or in vivo teratoma-formation assays. In 
keeping with these findings, METTL3 knockout mice were embryonic lethal at an early 
stage of development, with prolonged expression of pluripotency factors and failure to 
form the epiblast. These findings implied a failure to progress past naïve pluripotency.  
At the molecular level, detailed analysis of METTL3 knockout mESCs 
demonstrated increased transcript abundance and half-life of m6A-modified pluripotency 
genes in knockout mESCs, suggesting that m6A is required for the degradation of 
pluripotency genes51. These findings were accompanied by a global tendency towards 
stabilization of m6A-modified transcripts, in agreement with the results of the previously 
discussed YTHDF2 knockdown experiments52. An independent study evaluating existing 
sequencing of mESCs similarly showed that m6A-modified transcripts had half-lives that 
were up to 2.5 hours shorter than unmodified ones55. The decreased stability of m6A 
transcripts appears to be a generalizable trend across multiple contexts, as similar effects 
have been observed in the context of METTl3 depletion experiments in murine 
embryonic fibroblasts32, T cells56, mouse brain57, and HeLa cells58. Taken together, these 
experiments strongly support a global role for m6A in promoting transcript degradation, 
while also demonstrating the relevance of this molecular process to stem cell biology and 
cell fate decisions.  
While the aforementioned experiments provide evidence for m6A-mediated 
destabilization of transcripts, it is important to note that decreased transcript abundance 
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does not necessarily imply decreased protein expression. Dramatically enhanced 
translational efficiency might still paradoxically result in enhanced overall protein 
expression even in the context of a a diminished transcript pool. Indeed, isolated 
knockdown of the m6A reader YTHDF1 in HeLa cells results in decreased ribosomal 
occupancy of its m6A-modified targets without any corresponding changes in transcript 
abundance. This implies that the YTHDF1 normally functions to enhance the 
translational efficiency of a fixed transcript pool59. To address the apparent contradiction 
between the mRNA degradation effects of YTHDF2 and the translation-enhancing effects 
of YTHDF2, Wang et al. used a protein tethering assay in which the functional domains 
of YTHDF1 and YTHDF2 were fused to a small peptide, which could in turn bind to a 
specific RNA element in the 3’UTR of a luciferase reporter mRNA construct. These 
experiments confirmed that tethering of only YTHDF1 to the reporter increases 
translational efficiency while tethering of only YTHDF2 promotes transcript degradation. 
Simultaneous tethering of both reader proteins, leads to both a sharp peak in overall 
protein expression as well as enhanced transcript degradation. In theory, this mode of 
gene expression regulation would be ideal for rapidly induced bursts of protein 
expression, which can be rapidly silenced at the level of the transcript. Wang et al. 
speculated that this may be relevant during cellular differentiation events, responses to 
physiologic stimuli, and may serve to limit noisy gene expression59.  
While the above findings demonstrate a role for 3’UTR m6A in the regulation of 
translation, an independent mechanism of translation-regulation was described for m6A 
occurring in the 5’UTR. Translation initiation typically requires the formation of a 43S 
pre-initiation complex, which consists of the 40S ribosomal subunit and eukaryotic 
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initiation factors (eIF1-3). These components are recruited to the 5’ mRNA cap by the 
eIF4F complex, whose subunits achieve the combined function of binding the 7-
methylguanine (m7G) cap, and directing 43S assembly by binding to eIF360. However, in 
cellular stress conditions such as heat shock, the necessity of the 5’ mRNA cap can be 
bypassed to allow for ‘cap-independent’ translation. A series of in vitro translation 
experiments demonstrated that m6A-modified transcripts can bypass the requirement of 
the 5’ m7G mRNA cap nucleotide and the eIF4F complex. Cap-independent translation 
could be induced by the addition of a single m6A nucleotide anywhere within the 5’UTR, 
but not by m6A in the CDS. Reasoning that m6A must directly recruit one of the 43S 
preinitiation components to the 5’UTR, Meyer et al. performed protein-crosslinking 
experiments and identified eIF3 as an m6A-binding protein. Transcriptome-wide profiling 
confirmed significant overlap of eIF3 with m6A binding sites in the 5’UTR. Lastly, they 
substantiated the physiologic relevance of this phenomenon by showing that knockdown 
of the FTO eraser could increase 5’UTR m6A content and mediate increased cap-
independent translation during heat shock60.  
An independent study further examined the distribution of m6A, FTO & YTHDF2 
during heat shock.  In this study, heat shock resulted in an isolated increase in m6A 
methylation at the 5’UTR, with some specificity for heat shock transcripts. The shift in 
the m6A methylome coincided with relocation of YTHDF2 from the cytosol to the 
nucleus. Knockdown of YTHDF2 produced a specific loss of 5’UTR methylation and 
decreased expression of heat shock transcripts, suggesting its necessity during heat shock. 
In contrast, knockdown of FTO replicated the enhanced 5’UTR methylation observed in 
heat shock. These findings led to the hypothesis that during heat-shock, YTHDF2 binds 
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to 5’UTR m6A nucleotides and protects them from demethylation by FTO49. This would 
correspondingly lead to cap-independent translation and increased expression of heat-
shock genes. This model was supported by in vitro competition assays, and by the effects 
of YTHDF2 & FTO knockdown on 5’UTR methylation and translational efficiency of 
heat-shock transcripts49. Together with the description of eIF3 as an m6A reader, these 
two studies provide a detailed, integrated mechanism of action for the m6A machinery in 
heat-shock induced cap-independent translation.  
While both of these studies initially described heat shock induced cap-
independent translation to m6A, it is important to note that the enrichment of m6A in the 
5’UTR is now thought to be attributable to the dimethylated m6Am nucleotide. The 
specific pattern of enhanced 5’UTR methylation upon FTO knockdown made the original 
authors of the preceding publications suspicious that its true substrate was m6Am, rather 
than m6A. They subsequently showed that FTO has a several-fold higher degree of 
affinity toward m6Am, interacts specifically with m
6Am in the context of the 5’ cap, and 
preferentially demethylates m6Am compared to m
6A in a variety of assays61. These 
findings revise the role of FTO, and imply that at least some of the role of the m6A 
machinery in cap-independent translation and heat shock are attributable to m6Am. 
Notably, m6Am in the 5’UTR also exhibits distinct effects on transcript stability, as 
transcripts with m6Am tend to be protected from degradation by the decapping enzyme 
DCP234. 
In summary, m6A exerts complex, varying effects at the level of transcription and 
translation. Evidence drawn from a variety of contexts strongly supports the notion that 
m6A destabilizes transcripts by promoting degradation. This is certainly the case for 
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targets of YTHDF2, which are targeted to P bodies, where RNA degradation occurs52. It 
remains to be seen whether additional readers besides YTHDF2 function regulate the 
transcript stability of m6A modified transcripts, though results from METTL3 knockout 
experiments suggest that the majority of methylated transcripts tend to be downregulated 
transcriptome-wide51,55,56. Notably m6Am in the 5’UTR protects transcripts from 
decapping and degradation34.  
At the level of translation, YTHDF1 enhances translational efficiency of 
methylated transcripts bearing m6A in the CDS or 3’UTR. Methylation at the 5’UTR 
promotes cap-independent translation by direct assembly of the 43S preinitiation complex 
via recruitment of eIF3. While this mechanism can be stimulated by the addition of m6A 
anywhere in the 5’UTR in vitro60, it may be predominantly mediated by m6Am in vivo34. 
This mechanism mediates the cap-independent translation during the heat shock 
response, during which YTHDF2 re-localizes to the nucleus to protect modified 
nucleotides from demethylation by FTO49. While the YTHDF1- and YTHDF2-mediated 
effects of m6A on translation appear well-defined, it remains to be seen whether 
additional readers mediate distinct translation effects. Of note, only ~2,500 methylated 
transcripts were identified as YTHDF1 targets in knockdown experiments, representing 
only a quarter of m6A methylated genes59. When broadening the scope to all m6A 
methylated transcripts, the effects of METTL3 depletion vary depending on the context. 
In mESCs METTL3 knockout produced a global increase in translational efficiency, 
however this appeared to be specific for GC-rich transcripts independent of methylation 
status51. Another analysis of sequencing data from mESCs suggests decreased 
translational efficiency of m6A-modified transcripts55, while knockout in T cells results in 
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no detectable effects on translational efficiency56. These findings suggest that there may 
be additional reader proteins that are likely to mediate m6A-dependent effects on 
translation. 
Interactions between m6A and miRNA metabolism 
Among the possible regulatory roles for m6A in transcript metabolism, several 
interactions with the microRNA (miRNA) processing machinery have been described. 
The term miRNA refers to short, endogenously transcribed RNAs which bind to 
endogenous mRNAs via complementarity to target them for degradation by cleavage, 
translation repression, or deadenylation. Similar RNA-mediated regulation of gene 
expression are conserved across lower and higher organisms, and are broadly referred to 
as RNA interference (RNAi).  In mammals, miRNA processing begins with the 
transcription of a pri-miRNA, consisting of a ~22 nucleotide-hairpin with long flanking 
5’ and 3’ sequences. The pri-miRNA must then be metabolized by the microprocessor 
complex, consisting of the hairpin-binding protein DGCR8, and DROSHA, which 
cleaves the flanking 5’ & 3’ regions. This results in the formation of the pre-miRNA, 
which is exported to the cytoplasm, where the hairpin loop is cleaved off the pre-miRNA 
by Dicer, and Argonaute (Ago2), producing a double-stranded RNA duplex (dsRNA). 
This dsRNA then dissociates into mature single stranded miRNA, which recruits Dicer, 
Argonaute, and additional proteins referred to collectively as the RISC complex to 
mediate mRNA cleavage and degradation62.  
Whereas mammals rely on miRNAs to mediate gene expression, lower organisms 
such as yeast can also use the RNAi machinery to mediate co-transcriptional gene 
silencing by recruiting Dicer directly to nascent RNA transcripts. Surprisingly, 
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recruitment of the RNAi machinery to elongating chromatin-associated transcripts can 
also be detected in mESCs48. While Dicer is cytoplasmic in mammals and does not 
associated to chromatin, long-range ChIP for the microprocessor components DGCR8 & 
DROSHA shows that the microprocessor is bound to coding regions across the genome, 
in addition to the expected miRNA loci. In coding regions, recruitment of the 
microprocessor coincided with transcript degradation. This effect appears to be m6A-
mediated. METTL3 ChIP revealed a genome-wide correlation with DGCR8 binding, and 
METTL3 knockout led to loss of DGCR8 binding and stabilized transcript expression. 
This mechanism appears relevant to stress response, as heat shock resulted in recruitment 
of METTL3 and the microprocessors machinery to heat shock transcripts, resulting in a 
rapid spike in protein expression paired with a coinciding decrease in transcript half-life. 
This pattern of accelerated transcript with enhanced protein expression matches the 
expected effects of the m6A modification59, but is importantly dependent on both 
METTL3 and DROSHA, demonstrating the relevance of the microprocessor to this 
phenotype48.  
In an additional pair of studies, m6A and its putative reader hnRNPA2B1 were 
tied to traditional mammalian miRNA processing. In the first study, Alarcón et al. 
proposed that m6A nucleotides could act as recognition sites on pri-miRNAs for the 
recruitment of DGCR8 and DROSHA63. This hypothesis was based on the enrichment of 
the m6A consensus motif in miRNA sequences. METTL3 knockdown correspondingly 
produced decreased expression of ~70% of mature miRNAs, with an accumulation of the 
corresponding pri-miRNAs. Methylated pri-miRNAs were also more readily converted to 
pre-miRNAs in vitro. Recruitment of DGCR8 to miRNAs was METTL3-dependent, 
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though DGCR8 showed no preference for direct binding of m6A methylated transcripts in 
vitro, implicating a novel intermediary reader protein63. The same investigators 
subsequently identified hnRNPA2B1 as this intermediary. hnRNPA2B1 binding sites are 
similarly enriched for the m6A motif, and knockdown of this protein results in loss of 
miRNA expression and pri-miRNA accumulation that phenocopies the METTL3 
knockout. Co-immunoprecipitation confirmed a direct interaction between hnRNPA2B1 
and DGCR864. Thus, hnRNPA2B1 could reasonably serve as a link between m6A 
deposition and recruitment of the microprocessor machinery. These findings have 
recently been called into question, however, as hnRNPA2B1 does not replicate the 
binding patterns of other readers, nor does it contain a characteristic YTH domain65.  
Others groups have also not been able to replicate the link between hnRNPA2B1 and 
miRNA processing66.   
Lastly, the m6Am modification in the 5’UTR has also been associated with 
resistance to miRNA degradation. As previously discussed, transcripts bearing m6Am are 
resistant to DCP2-mediated decay. Since the miRNA machinery relies on decapping for 
mRNA degradation, it follows that m6Am-labeled transcripts are protected from the RNAi 







Regulation of RNA Splicing by m6A 
 Given the high frequency of m6A modifications, their predominant presence in 
mRNAs, and their enrichment in long internal exons29,30,51 many have been quick to posit 
a role for m6A in mRNA splicing. These findings are of interest given the preponderance 
of mutations in splicing factors, including SRSF2, U2AF1 and SF3B1, occurring in 
CHIP, MDS and AML. Given the relevance of alternative splicing in hematopoietic 
malignancy, it is conceivable that m6A-mediated alternative splicing may play a role in 
normal hematopoiesis and disease     
 The initial experiments examining METTL3 knockdown in hepatocellular 
carcinoma cell lines found that “multi-isoform” transcripts – those that altered their use 
of alternative exons without altering overall transcript abundance – were more likely to 
be methylated than single isoform transcripts30. METTL3 knockout in mESCs was 
similarly reported to result in significant splicing changes51. The m6A methyltransferase 
complex and erasers localize to nuclear speckles, which contain core components of the 
splicing machinery, supporting a potential interaction. Compellingly, depletion of the 
erasers ALKBH528 and FTO67 were both reported to regulate the recruitment of the 
splicing factor SRSF2 to RNA, and SRSF2 binding sites were enriched near m6A 
consensus motifs67.  
With respect to readers, both hnRNPA2B1 and YTHDC1 have been proposed to 
interact with m6A, and are well-established as splicing factors. Tandem-affinity 
purification experiments demonstrated that YTHDC1 interacts with several serine rich 
(SR) splicing factor proteins including SRSF1, 3, 7, 9 & 10, though no association with 
SRSF2 was found. Of these, knockdown of YTHDC1, SRSF3, and SRSF10 resulted in 
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significant alterations of splicing patterns. Based on additional experiments, the authors 
proposed that SRSF3 and SRSF10 compete for binding sites, and that YTHDC1 allows 
for recruitment of SRSF3 to prevent SRSF10 binding to RNA68. As discussed previously, 
there is some doubt as to the validity of hnRNPA2B1 as a direct m6A reader.  
Despite these reported findings, the notion that m6A mediates RNA splicing has 
been hotly contested, particularly by Ke et al. As discussed previously, m6A is deposited 
co-transcriptionally, and the m6A content of transcripts is >90% identical across 
chromatin-associated, nuclear, and cytoplasmic fractions. While over 98% of m6A 
residues were observed in exons, these were not found to be enriched near splice sites by 
m6A-CLIP/IP. Furthermore, Ke et al. analyzed raw sequencing data from previous 
publications and could not replicate their findings regarding splicing, suggesting that the 
original observations may have been byproducts of the bioinformatic analysis pipeline. 
They also performed RNA sequencing and m6A-CLIP-IP on previously analyzed 
METTL3 knockout mESCs, and found that methylated exons did not differ in their 
likelihood of splicing compared to unmethylated ones, as had previously been claimed46. 
Indeed, close examination of the published findings regarding YTHDC1 as an 
m6A reader reveals that the METTL3, SRSF3, and YTHDC1 knockdown conditions 
share only 160 mutually skipped exons, suggesting fairly low overlap genome-wide68. 
Taken together, these findings provide strong evidence that m6A is not necessary 




Cytokine Signaling & m6A Interactions in T Cell Biology 
 Examination of the effects of METTL3 deletion in CD4+ T cells in conditional 
knockout mice has unearthed both a compelling biological phenotype and a new 
paradigm for m6A-mediated regulation of gene expression in response to cytokine 
signaling56.  
 In this study, loss of METTL3 led to a dramatic increase in the proportion of 
naïve CD4+ T cells, which were resistant to activation in both in vitro and in vivo assays 
of T cell function. In adoptive transfer experiments, knockout T cells persisted in a naïve 
state with minimal proliferation, activation or differentiation. RNA-sequencing and m6A-
profiling revealed alterations in JAK/STAT signaling, as well as stabilization of three 
suppressor of cytokine signaling (SOCS) gene transcripts in the knockout condition. 
Typically, T cell activation and differentiation in adoptive transfer models are mediated 
by IL-7 signaling via JAK1/STAT5, which are known to be negatively regulated by 
SOCS. These observations and additional experiments led to the conclusion that IL-7 
signaling depends on m6A-modification and degradation of SOCS transcripts. In the 
absence of m6A, SOCS transcripts are stabilized, leading to persistent inhibition of 
JAK/STAT signaling, abrogation of IL-7 signaling, and persistence of naïve T cells56. 
Under this model, extracellular signaling is mediated by rapid alternations These 
observations point to further possible interaction points between normal hematopoiesis 
and the m6A machinery as JAK/STAT signaling and the SOCS genes have established 
roles in erythropoiesis69–71, and m6A may guide cellular fate decisions in this context.   
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Roles for m6A in Normal Hematopoiesis and Malignancy 
 Over the past year, evidence has begun to emerge regarding the role of m6A in 
normal hematopoietic stem cell behavior and malignancy. Epigenetic alterations appear 
to be a hallmark of MDS and AML, with well-established roles for aberrant DNA and 
histone methylation in disease pathophysiology. To date, it appears likely that this trend 
extends to alterations in RNA methylation. Below I discuss the established roles for the 
m6A machinery components in hematopoiesis and malignancy.  
METTL3 in Normal Hematopoiesis  
 As noted before, constitutive deletion of METTL3 in mice produces embryonic 
lethality early during development due to defects in the resolution of naïve pluripotency. 
METTL3 deletion enforces the naïve state of embryonic stem cells, and does not allow 
them to progress to the “primed” epiblast-like state in which they are able to differentiate 
into mature components of all three germ layers51.  
In contrast, morpholino-based silencing of METTL3 and METTL3 mutations in 
zebrafish produce a profound hematopoietic phenotype, with a decreased number of 
HSPCs and diminished contribution to erythroid, myeloid and lymphoid lineages. 
Typically the emergence of early HSPCs occurs in the aortogonadomesonephros (AGM) 
when a subset of AGM termed the haemogenic endothelium transitions directly into 
HSPCs (a process called the endothelial-hematopoietic transition, or EHT). The 
deficiency in early HSPC formation in zebrafish corresponded with a decreased number 
of haemogenic endothelial cells, and Zhang et al. correspondingly hypothesized that loss 
of METTL3 inhibited the EHT. Similar to the ‘locked-in’ state of METTL3 knockout 
ESCs, the zebrafish AGM would be lock in the endothelial state. Consistent with this 
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theory, RNA-seq of the AGM region in the METTL3 mutant zebrafish revealed 
upregulation of Notch, VEGF and vascular development pathways in the METTL3 
mutants, all of which maintain endothelial identity. The authors correspondingly 
identified m6A peaks in the notch1a transcript and demonstrated that while notch1a 
transcripts rapidly degraded in wildtype zebrafish, they were stabilized upon METTL3 
depletion. The hematopoietic defects could notably be rescued by small molecule 
inhibitors of notch signaling. Cumulatively, this led the investigators to conclude that loss 
of m6A in key transcripts genes such as notch1a lead to stabilization of endothelial 
identity, and inhibit EHT. 72.  
METTL3 in Malignancy 
Two studies have examined the effects of METTL3 knockdown in the context of 
human CD34+ HSPCs and AML cell lines.  Using publicly available gene expression 
data, both groups demonstrated that METTL3 is overexpressed in AML patients samples 
and cell lines compared to normal hematopoietic tissues38,73. Furthermore, among all 
malignancies, AML exhibits the highest levels of METTL3 expression, suggesting the 
possibility of m6A dependency in AML73. To this effect, CRISPR dropout screens 
targeted against RNA editing enzymes recurrently identified METTL3 and METTL14 as 
amongst the most necessary for AML cell line survival38. Consistent with these results, 
targeted knockdown or deletion of METTL3 in murine and human leukemia cell lines 
abrogated cellular proliferation without effects on apoptosis, and promoted differentiation 
of AML cells into normal myeloid cells based on flow cytometry for the mature myeloid 
marker CD11b38,73. Loss of METTL3 also resulted in decreased colony formation in 
semi-solid culture, and impaired engraftment in immunocompromised recipient mice. 
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METTL3 knockdown similarly resulted in enhanced differentiation and impaired colony 
formation in normal human CD34+ HSPCs73.  
These two studies investigated independent mechanisms to explain the observed 
effects. In one, the authors performed RNA-seq and miCLIP, which demonstrated 
enrichment of DNA damage, Myc and PI3K pathways amongst the differentially 
regulated m6A-modified transcripts. At the protein level, METTL3 knockdown led to loss 
of Myc, BCL-2, and regulators of PI3K73. The second study significantly expanded on 
the known role of the methyltransferase complex by demonstrating that METTL3 directly 
interacts with DNA promoters in ChIP experiments. Recruitment of METTL3 to 
promoter regions was mediated by CEBPZ, which recognizes CCAAT motifs in DNA. 
METTL3 binding in promoters corresponded to m6A modification of the associated 
transcripts, and enhanced translational efficiency without affecting overall transcript 
levels. Mechanistic studies suggested that in the absence of m6A, translation stalls at 
GAN codons (N= any nucleotide), inhibiting protein level expression. The transcription 
factors SP1 and SP2 were both dependent on promoter-bound METTL3 for effective 
translation, and rescue of SP1 expression could restore expression of its downstream 
target Myc, reversing the cell growth defects of the METTL3 knockdown cell lines38. 
Together these findings suggest that METTL3 is required for normal HSPC self-renewal 
and maintenance of AML leukemogenicity, and that these effects are mediated 
significantly by Myc. Importantly, the observed effects in cell lines may deviate from the 
impact of METTL3 deletion in native hematopoiesis in vivo. 
Interestingly, a tamoxifen-inducible murine model of METTL14 deletion was 
recently published. These mice demonstrated increased myelopoiesis at 11 days 
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following deletion, and diminished HSC engraftment in competitive repopulation assays. 
METTL14 was similarly shown to be upregulated in AML subtypes with specific 
chromosomal translocations. Myeloid transcription factors including PU.1 and CEBPA 
were found to be bound upstream of METTL3 in ChIP experiments using AML cells, and 
loss of PU.1 resulted in upregulation of METTL14. These findings implied that PU.1 
normally promotes myelopoiesis by downregulating METTL14. Consistent with previous 
reports, Myb and Myc were identified as downstream m6A-modified targets of 
METTL14 whose function was essential for leukemogenicity in AML cell lines40.  
Altogether, the general emerging consensus based on predominantly human and 
murine cell line data suggests that METTL3 is required for the maintenance of HSCs, and 
that loss of METTL3 promotes myelopoiesis. The same appears to hold true for 
METTL14. Results from multiple studies suggest that these phenotypes converge on Myc 
& Myb signaling. Notably, none of these publications remarked on significant splicing 
changes as a consequence of m6A depletion, perhaps calling into doubt the extent to 
which m6A acts as a regulator of alternative splicing.     
Contrasting Roles of FTO in AML 
 As discussed previously, our initial interest in the m6A machinery as a relevant 
target in AML was driven in part by the fact that both reported m6A demethylases are α-
KG dependent dioxygenases, and could therefore be implicated in the pathophysiology of 
IDH1/2 mutant AML. Over the past year, several studies have examined this possibility, 
as well as the role of FTO in non-IDH mutant AML.  
 Evidence implicating FTO downstream from IDH mutations was initially 
presented in a limited study performed in human embryonic kidney (HEK293T) cell 
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lines. In HEK293T cells bearing IDH mutations, m6A content was increased, and m6A 
levels could be normalized by treatment with the IDH1/2 mutant inhibitor AG221. These 
findings were consistent with the hypothesized 2-HG mediated inhibition of the m6A 
demethylases. Furthermore, knockdown of FTO alone increased m6A content in wildtype 
cells, replicating the IDH mutant phenotype. FTO knockout in IDH mutant cells, 
however, could not produce any further increase of m6A, suggesting that FTO may 
already be functionally inhibited in the mutant condition35. Because these experiments 
were performed in non-hematopoietic tissues, no meaningful assessment of the 
corresponding phenotype of FTO knockdown could be performed. Furthermore, a role 
for ALKBH5 could not be excluded.  
 In another study, FTO was counterintuitively found to be overexpressed in 
specific IDH1/2-wildtype AML subtypes. In murine models of MLL-AF9, FLT3-ITD, 
and PML-RARA driven leukemia, FTO was uniformly overexpressed, while ALKBH5 
was not. FTO overexpression promoted cell growth and viability, with decreased 
apoptosis in both murine and human AML cell lines, and enhanced leukemogenesis of 
MLL-AF9 murine leukemia. RNA-seq and miCLIP led to the identification of ASB2 and 
RARA as FTO and m6A-dependent transcripts essential to leukemogenic activity74.  
 This raised a possible contradiction. While increased FTO expression was 
apparently essential to certain subtypes of leukemia, its proposed role in IDH mutant 
malignancies would be dependent on decreased FTO expression. It is presumably 
unlikely that both gain and loss of FTO would be leukemogenic in distinct contexts.  
A resolution to this contradiction was proposed by the same group that published 
the role of FTO overexpression in non-IDH AML. By broadly examining the effects of 2-
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HG on 27 different human leukemia cell lines, Su et al. suprisingly, found that 2-HG 
treatment led to cell-cycle arrest and apoptosis in the majority of leukemia cell lines. This 
observation carried over to mouse xenotransplantation experiments, in which direct 2-HG 
treatment or introduction of IDH mutations led to decreased leukemic engraftment and an 
abrogated disease phenotypes. While the observed effects held true in a majority of the 
cell lines studies, Su et al. also identified several cell lines that were resistant to growth 
inhibition by 2-HG. By comparing 2-HG-resistant and –susceptible cell lines, they 
identified FTO as the only significantly differentially expressed α-KG dependent 
dioxygenase in susceptible cell lines. They further demonstrated that FTO is a target of 2-
HG in both in vitro and cellular assays, and that 2-HG treatment increases m6A content in 
resistant cell lines. In contrast, only 2-HG-resistant cell lines showed accumulation of 
5hmC mediated by Tet2. Ultimately, they find that Myc, cell cycle (G2M), and E2F 
signaling pathways were downregulated upon 2-HG treatment in the susceptible cell 
lines, and that these changes were m6A-dependent75. Of note, despite emerging evidence 
indicating that the true substrate of FTO is m6Am in the 5’UTR rather than m
6A, these 
authors maintain that loss of FTO in AML cell lines predominantly resulted in enhanced 
m6A in gene bodies. 
These findings suggest a significant revision of our understanding of IDH1/2 
mutations, as they imply that IDH1/2 mutations intrinsically inhibit growth and 
proliferation of leukemia. Though the authors comment that these mutations may still 
have a role to play in early leukemic transformation, the proposed dissociation in function 
between disease initiation and maintenance is unexplained. The classification of 2-HG-
resistant and -susceptible leukemic cell lines with distinct 2-HG-dependent effects is 
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another novel concept. The extent to which these findings in cell lines translate clinically 
is debatable. It is unclear, for example, if individual patients have exclusively FTO- or 
Tet2-dependent IDH1/2 mutant phenotypes, and whether this classification would 
correspond to diverging clinical outcomes. 
As the authors note, IDH1/2 mutations lead to relatively favorable outcomes in 
glioma, and some evidence indicates that the same may be true in leukemia. However, 
this phenomenon has been largely attributed to differential sensitivity to existing 
therapeutics, rather than intrinsic disease-abrogating effects of 2-HG. For instance, 
several groups have reported impaired DNA damage responses in IDH mutant cells, 
which render them susceptible to traditional chemotherapeutics and radiation25,76,77. 
Clinical trial results with small molecule inhibitors of IDH1/2 also indicate that inhibition 
of 2-HG is an independently viable therapeutic modality, as enasidenib produces 
differentiation of myeloid cells and clinical benefits in refractory AML78,79. Ultimately, it 
would be informative to replicate the experiments discussed above in IDH1/2 patient 
samples to determine if the proposed model from cell line observations is replicated in 





Hypothesis & Specific Aims 
Hypothesis:  
To date, many groups have published studies examining the effects of m6A RNA 
modification in human and murine leukemia cell lines. Several of these studies have 
suggested differential effects of m6A depletion on leukemic cells as compared to normal 
hematopoietic tissues. Our preliminary data suggest this is unlikely to be the case.   
Rather, we hypothesize that the m6A RNA modification regulates self-renewal 
and differentiation of hematopoietic stem cells, with corresponding effects on native 
hematopoiesis. Specifically we hypothesize that alterations in m6A levels mediated by 
deletion of the methyltransferase METTL3 and the m6A demethylase ALKBH5 will alter 
the frequencies of hematopoietic stem cells in the bone marrow of knockout mice, result 
in skewed hematopoietic differentiation. The observed phenotypes may have 
corresponding roles in myeloid malignancy, as has been reported elsewhere.   
Aim 1: Phenotypic Characterization of METTL3 & ALKBH5 Knockout in Normal 
Hematopoiesis 
 We will seek to characterize the effect of METTL3 and ALKBH5 deletion in 
native hematopoiesis by creating conditional knockout mice. Of note, mice with floxed 
METTL3 and ALKBH5 alleles allowing for Cre-mediated excision have recently been 
generated in the laboratory of Dr. Richard Flavell at Yale, which recently published 
effect of METTL3 knockout in CD4+ T cells56. These mice provide a powerful model 
system for the study of the m6A RNA modification in mammalian cells, and have been 
made available to us through collaboration with Huabing Li, of the Flavell lab, for 
characterization in the hematopoietic system. 
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 Cre-Lox genome editing systems rely on the recognition of short 34 nucleotide 
LoxP sites flanking a large genomic targets. The Cre recombinase specifically recognizes 
a pair of LoxP sites, and mediates excision of the “floxed” intervening DNA sequence, 
allowing efficient gene deletion. Tissue-specific deletion of target genes can be 
accomplished by expressing the Cre recombinase downstream of a tissue-specific 
promoter.  
 To accomplish tissue-specific deletion of METTL3 and ALKBH5, we crossed 
METTL3fl/fl and ALKBH5fl/fl mice to mice expressing Cre under the control of the Vav 
promoter, generating Vav-Cre METTL3fl/fl mice, herein referred to as VCM3 mice. Vav 
is constitutively expressed in all hematopoietic tissues, with expression beginning during 
early embryonic hematopoiesis at day 10.5. Importantly, Vav affects HSC homeostasis 
without affecting the endothelial-to-hematopoietic transition (EHT) in the AGM80,81. This 
allows for isolation of an HSC- intrinsic phenotype, independent of the previously 
reported effects of METTL3 deletion on EHT72. Global knockout of METTL3 is known 
to be embryonic lethal, and we anticipated that constitutive METTL3 deletion in the 
hematopoietic compartment in Vav-Cre+METTL3fl/fl mice would also result in non-viable 
embryos. With this in mind, we planned to use VCM3 mice to specifically address the 
role of METTL3 in fetal hematopoiesis by harvesting fetal liver at embryonic day 14.5 
(E14.5). The fetal liver is an early site of embryonic hematopoiesis, and represents a 
transit site of hematopoietic stem cells following their emergence in the AGM, and prior 
to their final settlement in the adult bone marrow.  
To assess the role of METTL3 in adult murine hematopoiesis, we will take 
advantage of inducible deletion mediated by expression of Cre under the control of the 
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Mx1 promoter in Mx1-Cre METTL3fl/fl mice, herein referred to as MCM3 mice. Mx1 is 
an interferon responsive-promoter, whose expression can is induced specifically in 
hematopoietic tissues and bone marrow stroma in response to treatment with poly-
inosine-poly-cytodilic acid. This allows for time-specific, tissue-specific deletion of 
METTL3 in the hematopoietic compartment in adult mice81. Results from the analyses of 
these mice are forthcoming, and preliminary findings are discussed below.  
Mice with global knockout of ALKBH5 have been derived previously and are 
known to be viable, though no specific analysis of the hematopoietic compartment has 
been published to date. We have similarly derived Vav-Cre ALKBH5fl/fl mice, herein 
referred to as VCA5 mice, for characterization.  
  We plan to characterize the hematopoietic phenotype of these mice by 
performing traditional assays of hematopoietic stem cell function. Specifically, we plan 
to perform: 1) Flow cytometry of fetal liver collected from embryos in the case of VCM3 
mice, or peripheral blood, spleen and bone marrow collected from adult MCM3 and 
VCA5 mice. This will allow us to assess for the relative frequencies of immature 
hematopoietic stem and progenitor cells (HSPCs), as well as the composition of mature 
myeloid, erythroid, or lymphoid lineages; 2) Competitive transplant assays: In these 
assays an equal number of mutant and wildtype total bone marrow cells are transplanted 
into a lethally irradiated recipient mouse, and the relative contribution of each population 
is tracked over time. This allows for direct assessment of the relative fitness of knockout 
HSPCs compared to wildtype; 3) Colony forming unit (CFU) assays: Formation of 
hematopoietic colonies in semi-solid culture is a defining feature of HSCs. These assays 
provide an assessment of the ability of these cells to differentiate into lineage-specific 
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precursors including erythroid, myeloid, granulocyte-macrophage and megakaryocytic 
colonies; 4) Stress hematopoiesis assays: To assess for subtler effects in the context of 
external stressors, we will assess the response of wildtype and knockout mice to specific 
stressors including treatment with the chemotherapeutic agent 5-FU, as well as serial 
phlebotomy.  
Aim 2: Molecular Characterization of VCM3, MCM3 and VCA5 mice 
 To correlate the observed phenotypes of VCM3, MCM3, and VCA5 mice to 
molecular events driven by m6A RNA modification, we will take advantage of 
fluorescence activated cell sorting (FACS) to prospectively identify specific subsets of 
hematopoietic cells of interest. Hematopoietic stem and progenitor cells (HSPCs) can be 
broadly identified by the exclusion of mature cells expressing lineage markers, in 
combination with the presence of the cell-surface markers Sca and cKit. This strategy 
identifies Lin-Sca+c-Kit+ (LSK) cells, which broadly capture the HSPC compartment. The 
LSK fraction can be further stratified based on expression of the Slam family markers, 
which allow for the identification of long-term HSCs (LT-HSCs), short-term HSCs (ST-
HSCs), multipotent progenitor (MPP), and more committed hematopoietic progenitor 
(HPC-1 & -2) populations82.  
  An ideal characterization of these knockout mice would involve a combination of 
RNA-sequencing, RNA-lifetime profiling experiments, miCLIP, and ribosomal profiling 
of wildtype- and knockout-derived LSK cells. Unfortunately, LSK cells are infrequent, 
representing 0.3-0.5% of the total marrow, with approximately 30,000 cells per mouse, 
and no techniques exist for meaningful expansion of murine HPSCs in culture. While 
RNA-sequencing and half-life determinations should be feasible owing to the relatively 
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small cell numbers require for RNA-seq, both miCLIP and ribosomal profiling require 5-
20ug of RNA, corresponding to approximately 30-50x106 cells33. This makes m6A 
profiling using primary murine tissues technically impossible.  
To circumvent this issue, we will make use of the ER-HOXB8 cell line, which 
can be derived from murine hematopoietic progenitors. These cells express the oncogene 
HOXB8 under the control of the estrogen receptor. While maintained in estradiol-
containing media, HOXB8 expression is enforced and these cells remain immortalized as 
myeloid precursors. Withdrawal of estradiol from the culture medium induces 
differentiation along the neutrophil lineage, and the extent of differentiation can be 
monitored by flow cytometry for the myeloid cell surface markers Gr1 and Mac183,84. 
This provides an ideal model system for the study of myeloid differentiation, and would 
provide unlimited cell numbers for miCLIP & Ribo-Seq characterization.  
An alternative approach would be to perform miCLIP and Ribo-Seq on less 
stringent subsets of hematopoietic cells. One reasonable option would be to isolate Lin-c-
Kit+ (LK) cells, which represent a larger overall fraction of the cells, while still enriching 
for HSPCs, which are uniformly c-Kit+. The obvious limitation to this approach is that it 
provides a less pure signal. Nevertheless, a similar approach has been used in the study of 
m6A in early hematopoiesis in zebrafish, in which the entire trunk region including the 
AGM was homogenized and sequenced. The data produced should ultimately be 
reflective of the m6A profile of hematopoietic precursors, and should rely the 
identification of some – but not necessarily all – relevant targets. 
Lastly, in addition to traditional bulk RNA-seq of LSK cells, we propose single 
cell RNA-sequencing (scRNA-seq) of LSK cells isolated from wildtype and knockout 
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mice. Where RNA-sequencing provides information about bulk changes in overall gene 
expression, scRNA-seq provides phenotype information, as cell identity can be inferred 
from transcriptional profile85. This would therefore allow for the identification of 
relatively more or less immature HSCs within the LSK fraction, while simultaneously 













Statement of Research 
I independently developed the hypothesis and initial experimental design for this 
work. I independently designed and performed the HOXB8 cell line experiments. Design 
of the VCM3 experiments was further developed with Dr. Halene & Yimeng Gao. The 
data in Figure 5 were independently collected and prepared by Yimeng Gao & Yuanbing 
Song. The experiments presented in Figures 6-9 were performed by Yimeng Gao & I, and 
the data were analyzed by Yimeng Gao. The VCA5 experiments presented in Figures 10-
13 were performed by Yimeng Gao & I, and I analyzed the data. I independently 
performed the experiments and analyzed the data for Figures 14 & 15. Bioinformatic 
analyses of RNA-seq data for Figure 16 & 17 were performed by Toma Tobaldi 
Statistics 
 All data presented were compared using unpaired two-tailed student’s t-test. 
Statistical significance indicated on graphs as follows: * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.001. Data are presented with mean +/- S.E.M. 
HOXB8 Cell Line Assays 
 HOXB8 cell lines were a gift of David B. Sykes and Peter Gaines, and were 
named the DBS and PG cell lines, respectively. The DBS cell lines were derived from a 
mouse expressing a GFP reporter downstream of the myeloid lineage gene Lysozyme. 
PG cell lines were derived from a wildtype mouse with no fluorescent reporter. HOXB8 
cells were cultured in OPTI-MEM with 10% heat-inactivated certified FBS, 2mm L-
Glutamine, 5U/mL pencillin G, 5ug/mL streptomycin sulfate with 2% SCF-conditioned 
mediated derived from CHO-SCF producer cell lines, with 0.5uM β-Estradiol. 
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Differentiation media was identical, with the exception of β-Estradiol, which was not 
used. We used anti-CD11b Pacific Blue and anti-Gr1 APC antibodies for flow cytometric 
assessment at 24, 48, 72, and 96h following β-Estradiol withdrawal.  
 Puromycin-selectable shRNAs targeted against METTL3 (TRCN0000039111, 
TRCN0000039112, TRCN0000039113) and FTO (TRCN0000183897, 
TRCN0000277143) were purchased from Sigma-Mission. These were assembled into 
Lentivirus by transfecting 293FT cells with a pCMV-VSV-G envelope vector, psPax2 2nd 
generation packaging vector, and the shRNA plasmid. Viral supernatants were collected 
every 24 hours for four days and purified using Millipore Centrifugal Filter Units (100K). 
HOXB8 cells were trasduced with lentivirus by plating 1x106 HOXB8 cells in 500 μL 
media in a 24 well plate with 8μg/μL polybrene, and 10μL virus. After 8 hours, 500μL 
fresh media was added, and after 24 hours, transduced cells were transferred into 6 well 
plates with 4mL additional media, with 3μg/μL puromycin.   
METTL3 & VCA5 Mice 
 METTL3 & ALKBH5 conditional knockout mice were a kind gift of Hua-Bing Li 
of the Flavell lab, generated as previously described56.  
Mouse Sacrifice & Sample Collection 
 VCA5 & VCM3 mice were sacrificed in accordance with existing IACUC 
guidelines and protocols. Mice were anesthetized with inhaled 30% Isofluorane, and 
peripheral blood samples were collected by retro-orbital bleeding. Sacrifice was then 
performed by cervical dislocation. Bone marrow samples were collected from femurs and 
tibia, with each bone flushed 3x with 1mL FACS buffer (PBS + 0.5% BSA + 2uM 
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EDTA). Spleen & thymus were harvested, mechanically dissociated in FACS buffer, and 
passed through a 40μm cell strainer (Falcon).  
Flow Cytometry Assessment of Fetal Liver & Bone Marrow Populations 
 Flow cytometry experiments were performed on a BD FACSARIAII. Red blood 
cell lysis was performed as necessary using ACK Red Blood Cell Lysis Buffer (Thermo 
Fisher). Samples were treated with purified rat anti-mouse CD16/32 (BD Biosciences) to 
block the Fc receptor as necessary. Samples were then stained with the appropriate 
antibody panels. Antibodies used include: anti-CD41 FITC (Pharminogen), anti-CD48 
Pac Blue (BioLegend), anti-CD150 PeCy5 (BioLegend), andti-CD105 PeCy7 
(BioLegend), anti-cKit APC (BioLegend), Lineage Biotion (BD Bioscience), 
Streptavidin APC-Cy7 (BioLengend), anti-Gr1 Biotin (BioLegend), anti-B220 Biotion 
(BioLegend), anti-CD11b Biotin (BioLegend), Streptavidin eFluor 450 (eBioSciences), 
anti-Ter119 (eBioSciences), anti-CD44 APC (BioLegend), anti-CD71 PECy7 
(BioLegend), anti-CD34 FITC (eBioSciences), anti-CD16/32 (eBioSciences), anti-Gr1 
APC (eBioSciences), anti-CD11b Pac Blue (eBioSciences), anti-CD3 FITC (BioLegend), 
anti-B220 APC-Cy7 (BioLegend), anti-CD45.1 PECy7 (Biolegend), anti-CD45.2 PE 
(Biolegend), anti-7/4 PE (Biolegend), anti-CD4 APC Cy7 (BioLegend), anti-CD8a Biotin 
(Pharminigen), anti-CD25 PE (BioLegend), CD44 PE-Cy5 (eBioSciences).  
Colony Forming Assays 
 10,000 fetal liver or bone marrow cells were mixed in 3mL of MethoCult GF 
M3434 for mouse cells (StemCell Technologies) and plated in triplicate. Plates were 




VCM3 Transplant Assays 
 Hematopoietic reconstitution assays with VCM3 mice were performed engrafting 
lethally-irradiated congenic CD45.1 Pep3/B 4-6 week-old recipient mice with 1x106 
CD45.2 VCM3 WT or KO fetal liver cells. Competitive transplant was performed with 
VCM3 mice by mixing 0.5x106 CD45.2+ VCM3 WT or KO fetal liver cells with an 
equal number of CD45.1+ competitor bone marrow cells and injected mixtures into 
lethally irradiated CD45.1/2 double positive recipient mice. Recipient mice in each group 
were matched for age & gender. Peripheral blood and bone marrow engraftment were 
assessed at 8 days post-transplant, consistent with the observed timeline of VCM3 KO 
mortality in hematopoietic reconstitution assays.  
VCA5 Competitive Transplant Assays 
 CD45.1/2 double-positive recipient mice were lethally irradiated (850 cGy) and 
engrafted with 0.5x106 CD45.2 VCA5 WT or KO total bone marrow cells, and an equal 
number of competitor CD45.1 Pep3/B total bone marrow cells. Peripheral blood 
chimerism was assessed every two weeks, starting at 4 weeks post-transplant.  
RNA Extraction & qPCR 
 RNA extraction was performed with the Qiagen RNeasy Mini Kit, and SYBR 
Green was used for qPCR quantification of transcript abundance (Thermo-Fisher). 
RNA Sequencing 
RNA-seq experiments were performed in biological triplicate on Illumina HiSeq 
2500. All programs were used with default settings. Raw reads were processed with 
Trimmomatic (v0.36) and aligned to the mouse genome (GRCm38) with STAR (v2.5.3a 
--quantMode GeneCounts), using the Gencode M15 transcript annotation as a 
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transcriptome guide. Normalization and differential analysis between Mettl3 WT and KO 
gene expression levels were performed with the edgeR Bioconductor package. 
Differentially expressed genes were identified with the following thresholds: 1) mean 
normalized counts per million > 1, 2) absolute log2 Fold Change > 0.75, 3) False 
Discovery Rate (FDR) < 0.05.  
Functional annotation of gene lists and enrichment analysis with Gene Ontology 
terms and Enrichr gene-set libraries (http://amp.pharm.mssm.edu/Enrichr/) were 
performed with the clusterProfiler and enrichR R packages. Enrichment with False 






METTL3 Knockdown Results in Delayed Differentiation of ER-HOXB8 Cells 
 To determine if the m6A machinery has a role in normal myelopoiesis, I 
performed shRNA knockdown of m6A writer & eraser proteins in the ER-HOXB8 
immortalized murine myeloid progenitor cell line. These cells express the oncogene 
HOXB8 under the control of the estrogen receptor. While maintained in estradiol-
containing media, HOXB8 expression is enforced and these cells remain as immature 
myeloid precursors. Withdrawal of estradiol from the culture media induces 
differentiation along the neutrophil lineage, and the extent of differentiation can be 
monitored by flow cytometry for the myeloid cell surface markers Gr1 and Mac183,84. 




Figure 1: Experiment schematic with representative differentiation time course. ER-HOXB8 cells 
underwent lentiviral transduction with shRNA targeted against FTO, METTL3, & ALKBH5, and 
puromycin selection. Following Estradiol withdrawal, ER-HOXB8 cells were allowed to 
differentiate, with flow cytometry for CD11b, Gr1, and GFP performed every 24 hours. Flow 
cytometry plots show a representative differentiation time course. Differentiation time course 




 I performed shRNA-mediated knockdown of METTL3 and FTO in two 
independently-derived ER-HOXB8 cell lines, labeled “DBS” and “PG”. The DBS cell 
line was derived from the marrow of mice expressing a GFP reporter under the control of 
the Lysozyme promoter, which serves as a surrogate indication of myeloid 
differentiation. The PG cell line was derived from wildtype murine marrow. Lentivirus 
was produced using shRNA plasmid purchased from Sigma, and cells were spinfected 
(Fig. 1). Knockdown efficiency was determined by qPCR. METTL3 knockdown of ~40-
70% was accomplished with three separate shRNAs (sh111, sh112, sh113) compared to 
control shRNA (shCOO2) and the untransduced (WT) parental cell line. FTO knockdown 
efficiency was ~50-55% (sh183), and ~75-80% (sh227) (Fig. 2). While I similarly 
attempted to derive ALKBH5 knockdown cell lines, these were variable in knockdown 
efficiency, and knockdown efficiency was frequently lost during culture and in vitro 
differentiation.  
 Figure 2: METTL3 knockdown efficiency by qPCR in A) DBS HOXB8 cells, B) 
PG HOXB8 cells; and FTO knockdown efficiency in C) DBS HOXB8 cells & D) 




 Surprisingly, METTL3 knockdown resulted in delayed differentiation, as 
reflected by delayed acquisition of the myeloid markers CD11b and Gr1 (Fig. 3).  This 
was consistent in both independently-derived cell lines. This effect was also uniform 
across all shRNAs targeted against METTL3. Data from 72h for the DBS cell line (Fig. 
3A) and 96h for the PG cell line (Fig. 3B) are shown as these were the most directly 
comparable time points, but the same trends were observed at 72h in the PG cell line. 
These results suggest that loss of METTL3 impairs myeloid differentiation in this in vitro 
model.  
Knockdown of FTO yielded less consistent results. While knockdown of FTO 
with sh227 did result in a striking delay in differentiation in both DBS & PG cells, 
knockdown with sh183 did not show any notable changes from untransduced cells or 
those transduced with control shRNA (Fig. 4). These results could be clarified further by 
repeating this experiment with additional shRNAs targeted against FTO, or by CRISPR 
mediated deletion of FTO.  
 
Figure 3: Flow cytometry for myeloid differentiation markers CD11b (Mac1) & Gr1 in 
METTL3 knockdown cell lines. A) DBS ER-HOXB8 cells at 72h after estradiol withdrawal 
and B) PG ER-HOXB8 cells at 96h after estradiol withdrawal. Data are shown for Parental 




 Importantly, these results are the product of a single pilot experiment which was 
not repeated. The consistent METTL3 knockdown phenotype across independently-
derived ER-HOXB8 cells lines and multiple shRNAs is striking. Nevertheless, these 
findings are not definitive. This would require replication of the results, and verification 
that the observed phenotypes are m6A-mediated by m6A quantification techniques and 
demonstration that the effect is reversed by rescue of METTL3 expression. These 
preliminary data did, however, provide an indication of a likely hematopoietic phenotype 







Figure 4: Flow cytometry for myeloid differentiation markers CD11b (Mac1) & Gr1 in 
FTO knockdown cell lines A) DBS ER-HOXB8 cells at 72h after estradiol withdrawal and 
B) PG ER-HOXB8 cells at 96h after estradiol withdrawal. Data are shown for Parental 




METTL3 is Essential for Murine Hematopoiesis 
 Having briefly examined a role for m6A in an in vitro model, we proceeded to 
characterize the hematopoietic phenotypes of VCM3 mice. I will refer to Vav-Cre+ 
METTL3fl/fl mice as VCM3 KO, Vav-Cre+ METTL3+/fl as VCM3 HET and VCM3 WT 
will refer to either Vav-Cre+ METTL3+/+ or Vav-Cre- METTL3fl/fl. 
Loss of METTL3 in the hematopoietic compartment of VCM3 KO mice was 
uniformly fatal. The yield of VCM3 mice from defined breeding pairs (Fig. 5A) deviated 
significantly from the expected Mendelian ratios (Fig. 5B, Table 1). Of the few VCM3 
KO pups that were born, all died shortly after birth. VCM3 KO pups demonstrated 
marked pallor and decreased size compared to HET or WT littermates (Fig. 5C).  
Given the apparent embryonic lethality of VCM3 KO mice, we analyzed fetal liver at 
embryonic day 14.5 (E 14.5). At this time-point, definitive hematopoiesis has emerged, 
and the fetal liver serves as the primary hematopoietic organ prior to migration of the 
hematopoietic system to the mature bone marrow. Of note, expression of Vav begins in 
primitive hematopoietic tissues at E11.5, allowing for Cre-mediated excision of METTL3 
after definitive HSC emergence80,86. Mendelian ratios at E14.5 were as expected (Fig. 
5B). Loss of METTL3 was confirmed in KO fetal liver by qPCR, while HET mice 
maintained expression similar to WT (Fig. 5D). VCM KO fetal liver exhibited decreased 
total cellularity compared to HET or WT (Fig 5E), and expression of key hematopoietic 
transcription factors Myb, Pu.1 and Rag1 were disturbed (Fig. 5F). Myb & Rag1 were 
increased in expression, while Pu.1 was downregulated. Of note Myb has been implicated 
as a target of m6A, while Pu.1 is believed to regulate the function of METTL1440. To 




Figure 5: Initial characterization of VCM3 mice. A) Breeding & experimental schematic        
B) Expected Mendelian ratios based on breeding schematic plotted against observed genotype 
ratios at birth and at time of fetal liver harvest at E 14.5. C) Appearance of VCM3 HET & 
VCM3 KO mice. D) METTL3 expression by qPCR on fetal liver hematopoietic tissue (n=3 
replicates per group) E) Fetal liver cellularity of VCM3 mice (n=3 per group) F) Expression of 
hematopoietic transcription factors by qPCR on fetal liver from VCM3 mice. (n=3 replicates 
per group).   
Table 1: Expected & observed Mendelian ratios. Mendelian ratios based on breeding 
schematic compared with observed ratios at birth, and at time of fetal liver analysis at E 14.5.  
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These findings indicate that METTL3 is essential for murine hematopoiesis, and 
that loss of METTL3 within the hematopoietic compartment is embryonic lethal. Based 
on the normal yield of VCM3 KO mice consistent with the expected Mendelian ratios at 
E14.5, lethality occurs at some point after the emergence of hematopoiesis at E14.5 (Fig. 
5C). The observed disturbances in cell number and gene expression do, however, indicate 
dysfunction at this early time-point.   
Altered Frequency & Function of HSPCs in VCM3 Fetal Liver  
 To assess the effects of METTL3 deletion on HSPCs, we assessed the frequency 
of distinct HSPC populations by flow cytometry. We first assessed the frequency of Lin-
c-Kit+ and LSK populations in VCM3 mice (Fig. 6A). VCM3 KO mice exhibited a 
significantly increased proportion of LSK cells, while the frequency of Lin-c-Kit+ cells 
was identical (Fig. 6B). There was a trend towards an increase in the Lin- fraction in KO 
cells that did not achieve statistical significance (Fig. B; WT vs KO: p=0.0503, HET vs 
KO: p=0.0975) due to small sample size (n=2 per group). Further examination of the 
LSK compartment showed increased frequencies of HPC-1 progenitor cells (CD150-
CD48+), which are predominantly lymphoid restricted progenitors, in VCM3 KO fetal 
liver (Fig. 6C, D). There was also a trend towards increased HPC-2 (CD150+CD48+). To 
assess the ability of VCM3 fetal liver HSPCs to contribute to definitive hematopoiesis, 
we performed colony forming unit (CFU) assays. CFUs provide a quantitative surrogate 
measure of the ability of HSPCs to differentiate along specific lineages. For these assays 
105 total fetal liver cells were plated in methylcellulose supplemented with hematopoietic 
growth factors in triplicate. Colonies were morphologically evaluated and counted 12-14 
days after plating. VCM KO fetal liver HSPCs gave rise to a significantly lower number 
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of total colonies, with a significant reduction of BFU-E (burst-forming unit – erythroid) 
and CFU-GEMM (granulocyte, erythroid, megakaryocyte, monocyte) (Fig. 6E). These 
results suggest impaired hematopoietic function despite the presence of an increased 
proportions of LSK HPSCs.  
Figure 6: Characterization of the HSC compartment in VCM3 mice. A) Gating of Lin-
Kit+ and LSK populations in VCM3 WT, HET & KO mice. B) Frequency of LSK, Lin-
Kit+ and Lin- cells in VCM3 mice, plotted as percentage of total marrow cellularity (n=2 
per group) C) Subgating of LSK population into Hematopoietic Stem Cell (HSC), 
Hematopoietic Progenitor Cell-1 & -2 (HPC-1, HPC-2) and Multipotent Progenitors 
(MPP)  D) Frequency of HSC, HPC-1, HPC-2 and MPP populations as percentage of total 
marrow cellularity (n=2 per group). E) Colony Forming Unit (CFU) Assay.  CFU-
GEMM: Colony Forming Unit Granulocyte-Erythrocyte-Macrophage-Megakaryocyte; 
CFU-GM Colony Forming Unit Granulocyte Macrophage; CFU-M: Colony Forming Unit 
Macrophage; CFU-G: Colony Forming Unit Granulocytes BFU-E: Burst Forming Unit 
Erythroid (n=3 per group). 
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 HSCs are functionally defined by their ability to serially reconstitute the full 
hematopoietic hierarchy in lethally irradiated recipient mice. Bone marrow 
transplantation assays therefore serve as the gold-standard assay of HSC self-renewal and 
differentiation. To determine if fetal-liver derived VCM3 HSPCs could reconstitute 
hematopoiesis, we engrafted lethally-irradiated congenic CD45.1 Pep3/B 4-6 week-old 
recipient mice with 1x106 CD45.2 VCM3 WT or KO fetal liver cells. While VCM3 WT 
fetal liver rescued lethally irradiated recipients, all VCM3 KO fetal liver recipients died 
by day 14, at the time of expected hematopoietic recovery (Fig. 7A). Correspondingly, 
engraftment of CD45.2 VCM KO cells was drastically diminished in the bone marrow 
and peripheral blood of recipient mice compared to those receiving WT fetal liver (Fig. 
7B-D).  
To ensure that decreased engraftment and mortality in these mice was not a 
technical artefact, we mixed CD45.2+ VCM3 WT or KO fetal liver cells with an equal 
number of CD45.1+ bone marrow cells and injected mixtures into lethally irradiated 
CD45.1/2 double positive recipient mice. This allows for tracking of the relative 
contributions of each competing donor population following transplantation. The degree 
of marrow chimerism is an indication of the relative fitness of HSPCs compared to the 
wildtype competitor marrow.  Whereas VCM3 WT cells repopulated recipient mice in 
equal proportion with CD45.1+ competitor cells, recipients receiving VCM3 KO marrow 
were almost entirely reconstituted by the CD45.1+ cells at 6 weeks, with few persisting 
CD45.2 cells (data not shown)  Cumulatively, these findings imply defective homing, 




To determine if VCM KO fetal liver HSPCs exhibit homing defects, we labeled 
VCM3 fetal liver cells with the membrane dye CFSE and injected them into lethally-
irradiated recipient mice. Recipients were euthanized 16 hours later, and engrafted donor 
cells were quantified by the combination of CD45.2 and CFSE (GFP) on flow cytometry. 
No differences in homing were detected, suggesting that VCM3 KO fetal liver HSPCs 
fail to reconstitute hematopoiesis due to loss of self-renewal or differentiation ability.    
  
Figure 7: Transplantation assay using VCM3 bone marrow. A) Survival curves for VCM3 
WT & KO mice. Mouse numbers and gender indicated on figure. B) Engraftment of CD45.2 
VCM3 WT or KO cells in the bone marrow and C) Peripheral blood of CD45.1 recipient 
mice at 8 days post-transplant. D) Engraftment of CD45.2+ VCM3 donor cells in the bone 
marrow and peripheral blood (n=2 per group). 
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VCM3 Fetal Liver Exhibits Altered Erythropoiesis 
 As noted previously, VCM KO pups that survived until birth exhibited marked 
pallor, and CFU assays showed decreased propensity for the formation of erythroid 
colonies. To explicitly assess VCM3 fetal liver for defects in erythropoiesis, we assessed 
the distribution of erythropoietic precursors based on CD44 staining of Ter119+ cells. As 
erythrocytes develop, they gradually decrease in size and lose expression of CD44. As 
this process occurs these cells progress sequentially through defined stages starting with 
the immature proerythroblasts (I), followed by the basophilic erythroblast (II), 
polychromatic erythroblast (III), orthochromatic erythroblast (IV), reticulocyte (V) and 
mature red blood cell (VI) stages87 (Fig. 8A). 
 
 Assessing this pattern of differentiation, we a found small but statistically 
significant increase in immature polychromatic erythroblasts (III), and a significant 
decrease in more mature reticulocytes (V). There were striking trends towards significant 
decreases in orthochromatic erythroblasts (IV) and reticulocytes (VI), but these failed to 
attain significance, again owing to low sample size (n=2) (Fig. 8B). These findings may 
be indicative of the early onset of an erythropoietic defect that may account for the 
Figure 8: Erythropoiesis in VCM3 fetal liver. A) Gating of erythrocyte precursors based on 
CD44 staining progression demonstrating Proerythroblasts (I), Basophilic Erythroblasts (II), 
Polychromatic Erythroblasts (III), Orthochromatic Erythroblasts (IV), Reticulocytes (V) and 
mature Red Blood Cells (VI) in VCM3 fetal liver. B) Frequency of erythrocyte stages I-VI as 
percentage of Ter119+ fetal liver cells (n=2 per group).  
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embryonic lethal phenotype, as well as the observed pallor of VCM3 KO mice that 
survived to birth.  
Myeloid Progenitor Depletion and Enhanced Differentiation in VCM3 Fetal Liver 
 Several studies have noted that differentiation blockade in AML cell lines 
resolves in response to METTL3 knockdown or knockout based on increased CD11b 
expression 38,73. Recently published evidence from inducible METTL14 knockout mice 
similarly suggests an increased leukocyte count, and enhanced myelopoiesis40.  
To explore the effect of METTL3 knockout on myeloid differentiation, we 
assessed the frequency of myeloid precursors and mature myeloid cells in VCM3 fetal 
liver. Myeloid progenitors including granulocyte-macrophage progenitors (GMP), 
common myeloid progenitors (CMP) and megakaryocyte erythroid progenitors (MEP) 
can be identified based on expression of FcRϒ (CD16/32) and CD34 (Fig. 9A), while 
mature myeloid cells were quantified by expression  of CD11b (Fig. 9C) and the 
activated neutrophil marker 7/4. These experiments showed a decreased number of GMP 
and CMP in VCM3 KO mice (Fig 9A,B), accompanied with a small, but significant 
increase in mature myeloid cells, from ~3.5% in WT or HET fetal liver to ~6.5% in KO 
liver (Fig 9C, D). There were few activated neutrophils overall, but there was a 
significant increase in 7/4+ neutrophils in VCM3 KO compared to WT & HET (Fig 9D).   
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These findings indicate depletion of myeloid progenitors with an increase in 
mature myeloid cells in VCM3 KO fetal liver. These findings are consistent with the 
previously published results, though it should be noted that myelopoiesis is limited in the 
context of the fetal liver, as reflected by the low overall frequency of myeloid cells. The 
effects of METTL3 on myeloid development would be further clarified through inducible 
knockout of METTL3 in adult murine marrow, in which myeloid cells are much more 
abundant.   
 
Figure 9: Myelopoiesis in VCM3 fetal liver. A) Representative data from VCM3 WT, HET 
& KO fetal liver illustrating gating scheme for myeloid progenitors including Common 
Myeloid Progenitor (CMP), Granulocyte-Macrophage Progenitor (GMP) & Megakaryocte-
Erythroid Progenitor (MEP). B) Frequency of GMP & CMP in VCM3 fetal liver plotted as 
percentage of total fetal liver cellularity (n=2 mice per group). C) Representative data from 
VCM3 fetal liver illustrating gating scheme for mature myeloid cells based on CD11b and 
Gr1 staining of VCM3 fetal liver. D) Frequency of CD11b+ and activated neutrophils (7/4+) 
as percentage of total fetal liver cellularity in VCM3 mice.  (n=3 mice per group). 
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Normal Myelopoeisis, Lymphopoiesis, and Erythropoiesis in VCA5 Mice 
 Having identified a prominent role for METTL3 in hematopoiesis, we next sought 
to determine whether the m6A demethylase ALKBH5 had corresponding effects. Of note, 
while knockout of METTL3 induces drastic, genome-wide reductions of m6A, loss of 
ALKBH5 results in very subtle changes in net m6A content of cellular RNA. Constitutive 
ALKBH5 knockout mice live normal lifespans, and their only reported phenotype thus 
far is altered spermatogenesis and decreased fertility28.  
 In the following text, I will refer to Vav-Cre+ ALKBH5fl/fl mice as VCA5 KO, 
Vav-Cre+ ALKBH5+/fl as VCA5 HET and VCA5 WT will refer to either Vav-Cre+ 
ALKBH5+/+ or Vav-Cre- ALKBH5fl/fl. 
 To assess for hematopoietic phenotypes in the conditional VCA5 KO mice, we 
first evaluated the proportion of mature myeloid and lymphoid tissues in 4-6 week old 
mice. The frequency of myeloid cells was assessed by flow cytometry for CD11b and 
Gr1, while the B & T cell compartments were assessed by B220 and CD3 expression, 
respectively. In two independent experiments, analysis of the bone marrow, peripheral 
blood and spleen revealed no significant differences in myeloid or lymphoid cell 
frequency between VCA5 KO and WT mice (Fig. 10A, B).  
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A previously published study showed that loss of METTL3 in CD4+ T cells 
results in persistently naïve T cells. To assess the effect of ALKBH5 knockout on T cells, 
we harvested thymus from 4-6 week old mice56. Staining with CD44 and CD25 allows 
identifies immature double negative (DN) T cell stages (DN 1-4)88,89. CD4 marks T 
helper cells, CD8 identifies cytotoxic T cells, and uncommitted double positive (DP) T 
cells express both (Fig. 11A, B). We observed no significant differences in these T cell 
populations in the thymus. This is consistent with the original T cell data, as METTL3 
KO mice had T cell phenotypes in the lymph nodes and spleen, but not in the thymus. We 
will need to analyze lymph node tissue for a more thorough characterization. 
 
 
Figure 10: Marrow, Spleen & Peripheral Blood Characterization of VCA5 mice.  
A) & B) Frequency of CD3+ T Cells, B220+ B Cells and Mac1+Gr1+ myeloid cells in the 
bone marrow (BM), peripheral blood (PB), and spleen of 4-6 week old VCA5 WT & KO 




Figure 11: Characterization of T Cell development in VCA5 mice. A) Diagram illustrating T 
cell immunophenotype during maturation. DN: Double Negative; DP: Double Positive Adapted 
from Fayard et al., 2010. B) Gating schematic for identification of DP, CD8+, CD4+ and DN T 
Cells, as well as DN subsets. C) & D) Frequencies of T cell populations in 4-6 week old VCA5 
mice. The two panels represent the results of two independent experiments (n=3 per group).  
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Next, we evaluated erythropoiesis using the same assessment of CD44 staining 
previously discussed. This revealed a trend towards decreased reticulocyte and mature 
RBC counts, but this was not statistically significant (Fig. 12). Moreover, complete blood 
counts performed on VCA5 KO mice did not exhibit anemia, and red blood cell indices 
did not differ significantly from WT (data not shown).     
Preserved Frequency and Colony-Forming Ability in VCA5 HSPCs 
We next turned our attention to the HSPC compartment. Quantification of LSK 
cells in the bone marrow of 4-6 week old VCA5 mice in two independent experiments 
demonstrated no significant difference in LSK abundance between VCA5 WT & KO 
mice (Fig. 13A, B). To determine if VCA5 HSPCs maintained colony-forming ability in 
vitro, bone marrow cells harvested from individual VCA5 WT or KO mice were 
harvested and plated in triplicate for CFU assays. There was no difference in colony 
formation between VCA5 WT & KO cells (Figure 13 C, D).  
  
Figure 12: Erythropoiesis in 4-6 week old VCA5 mice. Erythroid development based on A) CD44 
& Ter119 staining; B) Gating of erythrocyte precursors based on CD44 staining of Ter119+ 
erythrocytes, demonstrating Proerythroblasts (I), Basophilic Erythroblasts (II), Polychromatic 
Erythroblasts (III), Orthochromatic Erythroblasts (IV), Reticulocytes (V) and mature Red Blood 






Figure 13: HSPC frequency & function in 4-6 week old VCA5 mice.  
A) & B) Bone marrow frequency of LSK as a percentage of Lin- bone marrow cells, and as a 
percentage of total bone marrow cellularity in VCA5 mice (n=3 per group). Results of two 
independent experiments.  
C) & D) Colony forming unit (CFU) assays. Total bone marrow from littermate 4-6 week old 
VCA5 mice were plated in methylcellulose culture medium in triplicates, with colonies 
counted at day 14 (n=3 replicates per condition). Results of two independent experiments. 
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Diminished Chimerism of VCA5 KO Cells in Competitive Transplant 
 Given the apparently normal hematopoietic phenotype of VCA5 mice at steady 
state, we anticipated that VCA5 bone marrow would likely rescue hematopoiesis in 
lethally-irradiated recipients. We therefore elected to proceed with competitive 
transplantation to assess for subtler competitive advantages or disadvantages of VCA5 
KO marrow compared to wildtype. We engrafted lethally-irradiated congenic CD45.1/2+ 
recipient mice with 0.5x106 CD45.2+ VCM3 WT or KO fetal liver cells and an equal 
number of CD45.1+ competitor cells harvested from congenic Pep/3B mice, and then 
tracked engraftment of each donor population in the peripheral blood of recipient mice. 
As expected, VCM3 WT marrow exhibited roughly 50% chimerism in the 
peripheral blood of recipient mice, reflecting the equal fitness of their HSPC 
compartment compared with that of competitor Pep/3B marrow. In contrast, peripheral 
blood chimerism of VCA5 KO donor marrow was drastically reduced, accounting for 
only ~20% of peripheral blood cells in the recipient mouse. These results were highly 
statistically significant, and were replicated in an independent experiment (Fig. 14A, 
15A). To investigate the observed defects further, I assessed the relative frequencies 
myeloid and lymphoid cells within the CD45.2+ donor population. The relative 
frequencies of myeloid, B & T cells were similar in recipients receiving CD45.2+ VCA5 
WT or KO marrow (Fig. 14B, C, D). While there were some small, statistically 
significant differences in lineage composition at individual time points in the first 
iteration of this experiment, they were not replicated in the second (Fig. 15B, C, D). Of 





Figure 14: Competitive transplantation of VCA5 bone marrow.  
Recipient mice were lethally irradiated and received  5x10
5 
CD45.2 VCA5 KO (64 KO, n=6) 
or VCA5 WT(65WT, n=6; 68WT, n=5) bone marrow cells in competition with 5x10
5 
CD45.1 
Pep3b bone marrow cells. A) Engraftment of CD45.2 cells in peripheral blood assessed by 
flow cytometry (p<0.0001). Dotted line indicates 50% engraftment.  
Proportion of B) CD11b
+ 
myeloid cells (p=0.0396, 64KO vs 69WT) C) B220
+
 B cells 
(p=0.0363; 64KO vs 68WT) and D) CD3+ T Cells (p=0.0019; 64KO vs 65WT) (p=0.0017; 
64KO vs 68WT) within the donor CD45.2
+






Overall, these findings imply that the HSPC compartment of VCA5 KO mice is 
impaired in its ability to reconstitute hematopoiesis in competition with wildtype donor 
marrow, but this difference is not attributable to specific defective contributions to 
mature myeloid or lymphoid lineages. Determining whether these findings correspond to 
homing defects, decreased engraftment of specific HSPC populations, or other 




Figure 15: Results of repeat competitive transplantation assay. Recipient mice were lethally irradiated 
and received  5x10
5 
CD45.2 VCA5 KO (93 KO, n=5) or VCA5 WT (92 WT, n=4) bone marrow cells in 
competition with 5x10
5 
CD45.1 Pep3b bone marrow cells. A) Engraftment of CD45.2 cells in peripheral 
blood assessed by flow cytometry (p=0.0002 at week 4, p = 0.0007 at week 6). Dotted line indicates 
50% engraftment.  
Proportion of B) CD11b
+ 
myeloid cells (ns), C) B220
+
 B cells (ns) and D) CD3+ T Cells (ns) within the 
donor CD45.2
+




Gene Expression Changes in VCM3 KO Mice 
 Having characterized prominent hematopoietic phenotypes in the VCM3 & 
VCA5 models, we proceeded to characterize gene expression changes in these mice by 
RNA-seq. We elected to focus our analysis on the HPSC compartment. To this end, we 
isolated LSK from VCM3 WT & VCM3 KO fetal liver by fluorescence activated cell 
sorting (FACS), from which we extracted total RNA, which was subsequently polyA-
selected, and submitting for library preparation and sequencing. Sequencing of VCA5 
LSK is pending.   
 RNA-sequencing revealed upregulated expression of 701 genes (KO_up), and 
downregulated expression of 1395 genes (KO_down) in VCM3 KO LSK cells (Fig. 16A, 
B).  
 
Figure 16: Expression changes in VCM3 KO Fetal Liver LSK by RNA-seq. A) Transcript 
expression fold change (log
2
 FC) in KO compared to WT, plotted against expression level 
(counts per million, CPM) in VCM3 KO. B) Significance of expression changes plotted as 
negative logarithm of false discovery rate (FDR) versus fold change (log
2 
FC). 
METTL3 is highlighted in both plots. In both plots, genes that are significantly upregulated 





 METTL3 was >3-fold downregulated, confirming effective gene deletion. 
Interestingly, the methyltransferase components WTAP & RBM15 were upregulated, as 
was the m6A reader YTHDF2.    
Figure 17: Enrichment analyses of expression changes in VCM3 KO LSK.  
A) Enrichment of genes upregulated in VCM3 KO (KO_up) and genes downregulated in 
VCM3KO (KO_down) in chromatin immunoprecipitation (ChIP) data sets available in the 
ChEA enrichment analysis tool.  
B) Enrichment of KO_up & KO_down genes amongst genes that are differentially 
downregulated in response to experimental manipulation of a single gene. OE indicates data 
sets in which the indicated genes were over-expressed, KO indicates knockout. Experimental 
data sets were drawn from the Gene Expression Omnibus (GEO) data sets.  
C) Enrichment of KO_up & KO_down genes among genes that are differentially expressed in 
response to transcription factor loss of function. Experimental data sets were drawn from 
GEO.  
Significance of enrichment is color-coded as described. Gene counts for non-significant 




Enrichment of Differentially Expressed Genes in ChIP Data Sets  
To assess general pathways and processes that might be enriched within the 
differentially expressed genes observed in VCM3 KO LSK, we compared the list of 
differentially expressed genes to results from existing experimental data available from 
the Chromosome Enrichment Analysis (ChEA) tool, and the Gene Expression Omnibus 
(GEO) data sets.  
We first searched for enrichment of our differentially regulated genes as targets of 
chromatin binding proteins based on available chromatin immunoprecipitation (ChIP) 
data (Fig. 17A).  Consistent with previously published results, we found that upregulated 
genes in VCM3 KO (KO_up) were chromatin binding targets of STAT556, Notch172, 
SPI140, Myc38,73 and Myb40,73. KO_up genes were also enriched for binding targets of the 
transcription factor NCOR, which functions upstream of Notch signaling in zebrafish to 
mediate HSC emergence in the AGM90, and is mutated in MDS91. KO_up genes were 
also enriched for binding by BRD4, a chromatin reader protein that binds to acetyl-lysine 
and has been implicated as a therapeutic target in AML92–94.   
Genes that were downregulated in VCM3 KO (KO_down) were enriched for 
targets of DROSHA (Fig. 17A). This would be expected based on the interactions 
between METTL3 and the microprocessor machinery in miRNA biosynthesis63,64, and 
could be consistent with the reported role of METTL3 in co-transcriptional gene 
silencing48. Interestingly, KO_down genes were enriched as targets of RNF2, MTF2, 
SUZ12, and EZH2. EZH2, SUZ12 and MTF are all of which are components of the 
Polycomb repressor complex 2 (PRC2). PRC2 mediates H3K27 trimethylation, which is 
a histone repressive mark important for gene silencing. RNF2 is an E3 ubiquitin ligase 
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and polycomb group protein that associates with PRC1 & PRC295.  Loss and gain of 
EZH2 occur in distinct hematopoietic malignancies96,97, and it has been investigated as a 
therapeutic target in AML98.   
Genes that were differentially regulated by METTL3 and bound by EZH2, SUZ12 
or RNF2 were frequently bound by multiple components of the polycomb machinery, 
increasing our confidence in their identity as potential PRC targets (Fig.18). 
Differentially regulated genes in VCM3 KO bound by two or more components of the 
polycomb machinery include CDKN2C, CDKN1C99, Sox6, Pax5100, Bach2101, and 
Hoxa5, all of which have reported roles in hematopoiesis. This implies the possibility of 
METTL3-dependence of the PRC2 complex, which may correspond to hematopoietic 
phenotypes.  
 
Figure 18: Mutual binding of differentially expressed genes in VCM3 KO LSK by Polycomb 
proteins.  
Venn diagram illustrating the number of differentially bound genes in VCM3 KO LSK as 




Enrichment of Differentially Expressed Genes in Gene Perturbation Data Sets  
 We next examined RNA-seq data sets available from experiments in which the 
expression of single genes were perturbed by overexpression, mutation or knockout.  
We first examined transcripts that were downregulated by experimental 
perturbation of individual genes in these data sets (Fig. 17B). We found that genes that 
were downregulated in response to Rb1 knockout, E2F8 knockout and ABL1 mutation 
were similarly downregulated by METTL3 deletion (KO_down). Genes that were 
downregulated in response to KDM1a knockdown were upregulated by METTL3 
deletion (KO_up). Genes that were downregulated in response to CEBPα knockout or 
STAT1 knockout could be either KO_down or KO_up in VCM3 LSK (Fig. 17B).  
We then examined RNA-seq data sets for transcripts that were upregulated in 
response to experimental gene perturbation. This showed that genes upregulated in 
response to Akt1 knockout, CEBPα knockout, or Myc knockout tend to be KO_down in 
VCM3 LSK, while genes upregulated in response to KDM1a also tend to be KO_up. 
(data not shown).  
Akt, Myc and CEBPα have previously been implicated in METTL3 knockdown 
experiments in hematopoietic cells, while KDM1a represents a novel target. Rb1 and 
E2F8 interestingly synergize during terminal erythroid differentiation, and their absence 




Enrichment of Differentially Expressed Genes in Transcription Factor LoF Data 
Lastly we examined data sets in which transcription factor loss of function (LoF) 
experiments were performed for enrichment of VCM3 KO_up and KO_down genes.  
Loss of RBM15 was synonymous with loss of METTL3 for a subset of targets, as 
genes which were upregulated in response to RBM15 LoF were exclusively upregulated 
in VCM3 KO, and those that were downregulated after RBM15 knockout were 
correspondingly downregulated in VCM3 KO (Fig. 17C). A small group of genes that 
were upregulated in response to SRF LoF were KO_down. Genes that were upregulated 
in response to Myc LoF could be either KO_up or KO_down.  
The synonymous findings for RBM15 LoF and METTL3 KO are as expected, as 
RBM15 is a known methyltransferase component, which assists in the recruitment of 
METTL3 to specific targets. The perturbation of SRF targets in METTL3 KO is worth 
noting, as SRF1 is a transcription factor that is essential for megakaryopoiesis102,103. SRF 
is co-activated by MKL1/2 which, as mentioned previously, is one component of the 









Here I have presented an initial phenotypic characterization of the VCM3 and 
VCA5 mice. In summary, VCM3 KO mice have a striking embryonic lethal phenotype, 
with an apparent increase in fetal liver LSK frequency, decreased myeloid progenitors 
with mildly increased mature myeloid cell production and defective erythropoiesis. 
Despite the increased LSK frequencies in VCM3 KO fetal liver, the HSPC compartment 
of these mice was defective in classic assays of self-renewal and differentiation. VCA5 
mice appear to have no hematopoietic phenotype in steady-state, but are at a marked 
disadvantage in competitive transplant assays against wildtype bone marrow.  
Apparent LSK Expansion in VCM3 KO Mice 
From the current results, it is unclear whether transplanted VCM3 KO HSPCs 
persist in the recipient bone marrow and simply fail to proliferate and differentiate, or are 
eliminated over time. Unfortunately, we injected a small number of cells (1x106) during 
these transplant experiments, and did not analyze enough marrow cells to accurately 
assess the remaining number of donor HSCs post-transplant. We did confirm that there is 
no difference in HSPC engraftment between WT & KO cells at 16 hours following 
transplantation using fluorescent dyes. It would be of interest to perform similar 
fluorescent labeling and tracking experiments at later time points to assess the extent of 
wildtype compared to mutant proliferation. In future experiments we will have to assess 
entire marrow samples by flow cytometry to obtain a quantitative assessment of 
remaining cell numbers.  
The expansion of the LSK compartment in VCM3 fetal livers coupled with their 
failure to rescue hematopoiesis in transplant experiments presents a compelling question. 
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It seems counterintuitive that a genetic alteration would simultaneously enforce HSC 
identity while preventing meaningful differentiation. Interesting analogies can be drawn 
to METTL3 deletion in other contexts. In the case of CD4+ T cells, METTL3 deletion 
leads to persistence in a naïve, undifferentiated state, with dramatically reduced 
proliferation following adoptive transfer. In this case, the phenotype is driven by a lack of 
responsiveness to cytokine signaling, as JAK/STAT signal transduction downstream of 
IL-7 is prevented by the persistence of SOCS gene expression in the absence of m6A56. 
METTL3 deletion in murine embryonic stem cells results in a strikingly similar 
phenotype. These mESCs remained locked in a “ground” state, unable to resolve naïve 
pluripotency. As a consequence, knockout mESCs fail to contribute to meaningful 
chimera formation in embryo complementation assays and fail to form teratomas when 
injected into recipient mice. Weeks after injection into recipient mice for teratoma-
forming assays, the mESCs can be retrieved and continue to propagate in culture, 
reflecting sustained self-renewal, and persistent pluripotency51.  
Our results examining VCM3 KO fetal liver HSPCs are reminiscent of the 
phenotypes of METTL3 knockout T cells and ESCs. Hematopoiesis ultimately fails, 
owing in part to defective differentiation, despite an increase in the immature LSK 
population. Pending analysis of larger amounts of bone marrow post-transplant may 
reveal persistence of transplanted, quiescent HSCs that tail to proliferate, similar to the 
persistently naïve METTL3 KO CD4+ T cells. Unfortunately there is no simple assay for 
HSC self-renewal. HSCs cannot be propagated in culture like ESCs, as they differentiate 
spontaneously within days. The theoretical gold standard assay for self-renewal is serial 
hematopoietic reconstitution in transplants, but this also depends on intact differentiation. 
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It is unclear which mechanisms may dictate this phenotype in HSCs – it is 
possible that, similar to T cells, m6A-mediated responses to external cues such as 
cytokine signaling may be necessary for differentiation. In this case, the problem would 
be lack of response to an external pro-differentiation stimulus. Alternatively, VCM3 KO 
HSCs may rely on m6A-mediated degradation of HSC-specific self-renewal transcripts 
for differentiation. In this case, the barrier to differentiation would be intrinsically 
enforced “stem-ness”. RNA sequencing results from VCM3 WT & KO LSK cells are 
forthcoming, and may reveal whether one or both of these mechanisms is at play in 
HSPCs.       
Decoupling HSC & Myeloid Phenotypes 
In AML cell lines and human CD34+ cells, knockdown or knockout of METTL3 
produces increased myeloid differentiation and abrogated leukemogenesis38,73. Loss of 
METTL14 similar results in myelopoiesis, and is negatively regulated by the core 
myeloid transcription factor PU.140. How do we reconcile this apparently increased 
differentiation in cell lines with the increased fraction of immature LSK observed in our 
knockout mice? It is worth noting that in our VCM3 KO fetal liver, there is a small but 
statistically significant depletion of myeloid progenitors and increase in mature myeloid 
cells, which resembles the results of cell line experiments. Ultimately this apparent 
contradiction may depend on the extent to which human CD34+ cells and AML cell lines 
resemble immature HSCs as opposed to more committed progenitors. The cell of origin 
in AML, for instance, is thought to be a more committed myeloid progenitor which 
inappropriately gains the ability for self-renewal. AML cells are accordingly lineage 
restricted, and likely do not recapitulate a strong HSC identity. Similarly while CD34+ 
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human samples are enriched for HSCs, they are highly heterogeneous. CD34 is expressed 
on all progenitor cells including CMP, GMP and MEP, and the bulk of patient samples 
are composed of these more frequent populations. As a result, the effects of METTL3 
depletion on immature HSCs may be distinct from those seen in more committed myeloid 
progenitors. Loss of METTL3 may induce differentiation of myeloid progenitors, 
producing the observed increase in mature myeloid cells which we observe in VCM3 KO 
fetal liver, and which are seen in AML cells and CD34+ cells. However, it is also 
possible that more immature HSC-like cells are prevented from differentiating, as we see 
in the LSK compartment.  
Of note, we have analyzed bone marrow from a small number of Mx1-Cre 
METTL3f/f (MCM3) mice following induction of Cre expression by pIpC injection. 
These mice exhibit a similar accumulation of immature LSK cells, and show prominent 
leukopenia and thrombocytopenia on complete blood count assays, rather than increased 
myeloid cell counts (data not shown). The MCM3 mice will provide a more robust model 
to assess the effect of METTL3 deletion on myelopoiesis over time, which is not possible 
in the fetal liver model. Furthermore, the adult marrow provides a more suitable system 
to assess the effect on myeloid differentiation, as myelopoiesis is a much more abundant 







Limitations to METTL3 as a Therapeutic Target 
Given the overexpression of METTL3 in AML cell lines compared to normal 
hematopoietic tissue, there has been interest in targeting the methyltransferase 
therapeutically. METTL3 knockdown or knockout produce enhanced myeloid 
differentiation and abrogate leukemogenicity in mouse models. However, the prospects 
for METTL3 as a therapeutic target depend on the degree of AML cell dependence on 
m6A, the level of toxicity caused by inhibition in normal tissues, and the ability to 
differentially target METTL3 in leukemic cells. Because METTL3 is a wildtype protein 
that is simply overexpressed, there is no basis for selectivity of drug effect towards 
METTL3 in leukemic cells as opposed to cells. It is therefore likely that any small 
molecule inhibitor of METTL3 would produce similar reductions in methyltransferase 
activity in diseased and normal cells, with a consequent likelihood of toxicity. It is 
theoretically possible that mild reductions in METTL3 activity could resolve 
differentiation blockade in leukemic cells, without inducing toxicity in normal tissues 
(i.e. a “therapeutic window”). However the experiments thus far have relied on high 
degrees of knockdown or complete knockout to achieve differentiation of AML cell lines. 
If complete loss of METTL3 is required for “therapeutic” effect, it is likely that toxicity 
would ensue from simultaneous inhibition of METTL3 in wildtype tissues. As the VCM3 
mice demonstrate, METTL3 function is essential for normal hematopoiesis, and produces 
rapid embryonic lethality. Our early results from MCM3 mice suggest that they develop 
prominent cytopenias. It is therefore extremely likely that small molecule inhibitors of 
METTL3 would have a very narrow therapeutic window and small therapeutic index. 
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Attempts at developing therapeutics may be better targeted towards known 
upstream regulators of METTL3, or its downstream targets, which may produce more 
subtle effects. Upstream regulators include PU.140. Downstream targets include Myc, 
Myb, SP1, and SP238,40,73. Recently a novel therapeutic modality was developed for 
targeting Myb – this may be particularly effective in METTL3-overexpressing 
leukemia105.  
Stress Phenotype of VCA5 Mice  
Disruption of the m6A demethylase ALKBH5 in VCA5 mice produces a much 
more subtle phenotype than that seen in VCM3 fetal liver. This is in keeping with the 
established phenotype of constitutive knockout mice, which only exhibit deficiencies in 
spermatogenesis and fertility. As noted previously >90% of m6A nucleotides are 
conserved between chromatin-associated and nucleoplasmic RNA, and >98% of m6A 
sites are identical between nucleoplasmic and cytoplasmic RNA in HeLa cells at steady-
state. These findings suggest m6A demethylation may not play a meaningful physiologic 
role at steady state45. Nevertheless, marked remodeling of the epitranscriptome landscape 
is observed under stress conditions. A particularly well characterized example is during 
heat-shock, during which METTL3 re-localizes to specific targets, and YTHDF2 must be 
recruited to protect heat-shock transcripts from demethylation by FTO48,49,60. While the 
role of FTO as an m6A demethylase remains the subject of debate, these findings 
potentially implicate the m6A demethylases in adaptive cellular responses. Differentiation 
represents a cellular transition state mediated predominantly by epigenetic events. Cells 
in the hematopoietic hierarchy – with the special exception of B & T cells, which are 
subject to somatic recombination – share the same DNA content, but their identity is 
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dictated by distinctive patterns of gene expression, which are in turn controlled by DNA 
methylation, histone conformation, and distinct networks of transcription factor 
expression. Changes in RNA methylation may act as a necessary event during 
differentiation, as is the case during the resolution of naïve pluripotency in embryonic 
stem cells51. While absence of ALKBH5 is clearly not a barrier to establishing an intact 
hematopoietic system, the deficiencies of VCA5 KO mice compared to wildtype in 
competitive transplant assays may be an indication of developmental rigidity and delay in 
dynamic responses to hematopoietic stress. We intend to explore this possibility further 
by subjecting VCA5 mice to stressors such as chemotherapy treatment with 5-
fluorouracil or phlebotomy. The relatively mild phenotype of the VCA5 mice may also 
be due to compensation of demethylase activity by FTO or other potentially unknown 
m6A demethylases. In this regard, examination of ALKBH5 & FTO double-knockouts 
may be of interest.  It will be important to exclude homing defects as an underlying cause 
for the in competitive transplant phenotype, as we did in the case of VCM3 transplants. It 
is worth noting that spermatogenesis, the sole area in which VCA5 mice appear deficient, 
represents a similar epigenetic transition as the germline must be wiped clean of key 








Possible Mechanisms of METTL3 Function in Hematopoiesis 
 Our RNA sequencing data provide a glimpse at potential mechanisms that may 
underlie the hematopoietic phenotypes observed in VCM3 KO fetal liver. Importantly, 
differential expression at the transcript level does not always correlate to protein level 
alterations, and we will need to perform ribosomal profiling to determine the translational 
efficiency of target transcripts. We will similarly need to perform miCLIP to determine 
which changes in transcript-level expression are accounted for by m6A methylation, and 
which are a result of secondary effects. Nevertheless, these preliminary data merit 
discussion.    
As outlined briefly in the results, differentially expressed genes identified in 
RNA-sequencing of VCM3 KO fetal liver LSK were enriched as targets of chromatin-
binding proteins with known roles in hematopoiesis. Several differentially expressed 
genes in VCM3 KO were mutually regulated by important hematopoietic transcription 
factors, signaling proteins and epigenetic modifiers.  
 Differentially regulated VCM3 KO transcripts were enriched for targets of the 
chromatin reading enzyme BRD4, as identified by ChIP. BRD4 is a bromodomain 
protein that mediates assembly of transcription factors near acetylate histones with a 
tendency towards enhancement of transcription92. Small molecule inhibitors of BRD4 
have been applied to the treatment of various subtypes of AML, including in those with 
MLL rearrangements94. Leukemia with IDH2 mutations also appear susceptible to BRD4 
inhibition93. If the pro-differentiation effects of METTL3 depletion observed in AML cell 
lines are in part mediated by inhibition of BRD4, then METTL3 overexpression could be 
used as a biomarker for sensitivity to BRD4 inhibitors. BRD4 target transcripts are 
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upregulated in VCM3 KO, which suggests that METTL3 deletion does not pheno-copy 
BRD4 inhibition, as we might expect transcriptional repression of BRD4 targets. 
However, it is important to note that inhibition of BRD4 does not necessarily have 
straightforward inhibitory effects on transcription. As a result, a role for BRD4 in 
METTL3 overexpressing AML is still a possibility worth considering.  
 Genes that were downregulated in VCM3 KO LSK (KO_down) were 
interestingly enriched for targets of EZH2, SUZ12 RNF2, and MTF2 in ChIP Data. 
EZH2 & SUZ12 are two of the core components of the Polycomb Repressor Complex 2 
(PRC2). As discussed previously, PRC2 deposits the H3K27me3 repressive histone 
modification, which is responsible for durable silencing of gene expression. MTF2 is a 
non-constitutive element of PRC2106, and RNF2 is also a polycomb protein. PRC2 is 
known to be necessary for ESC differentiation107,108, and is implicated in hematopoiesis 
and myeloid malignancies96,98. The fact that PRC2 targets were uniformly downregulated 
in VCM3 KO LSK suggests that METTL3 may normally function to prevent silencing of 
gene expression by PRC2. Two possible mechanisms for this function are conceivable. 
First, given that METTL3 is known to interact directly with chromatin38,48, it could either 
directly antagonize PRC2 binding or mediate local effects at target DNA sequences to 
maintain an open chromatin conformation and prevent PRC2 binding (Fig. 19A). 
Alternatively, METTL3 inhibition of PRC2 could be dependent on m6A RNA. Recent 
evidence shows that the recruitment of PRC2 to target DNA can be directly inhibited by 
RNA109. In this case, RNA acts as a competitive decoy, as PRC2 binding to RNA or 
DNA is mutually exclusive. It is conceivable that RNA binding to PRC2 is dependent on 
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m6A methylation of the target RNA substrate (Fig. 19B). This would provide a 
fascinating link between the epitranscriptome and epigenome. 
To examine this possibility further, we will assess distribution of H3K27me3 and 
PRC2 in VCM3 fetal liver by immunofluorescence and ChIP.  We can further assess 
whether METTL3 binds directly to potential PRC2 targets by examining existing 
METTL3 ChIP data. If this effect does not appear to be mediated by chromatin-binding 
of METTL3, then the RNA-mediated mechanism could be investigated by biochemical 
assays.  
A final possible molecular mechanism that may explain part of the VCM3 fetal 
liver phenotype based on our preliminary RNA-seq data involves Rb & E2F8. Rb is a 
well-known tumor suppressor, and both Rb & E2F8 are involved in cell cycle regulation. 
Knockdown of either Rb or E2F8 results in downregulation of a set of transcripts that are 
also downregulated in VCM3 KO LSK, as discussed in the results. Compellingly, Rb and 
E2F8 normally function synergistically to promote terminal erythroid differentiation, and 
loss of either protein results in aberrant erythropoiesis and anemia87, similar to what we 
have observed in VCM3 fetal liver and in preliminary analyses of MCM3 adult marrow. 
It is possible that METTL3 is necessary for appropriate function of Rb & E2F8.  This 
developmental axis may therefore account for the erythropoietic phenotype observed in 
VCM3 fetal liver, and would merit further investigation if it is supported by forthcoming 





Figure 19: Hypothesized Mechanisms of PRC2 Inhibition by 
METTL3.  
A) Chromatin-mediated mechanism in which METTL3 
binding directly antagonizes PRC2 binding, or METTL3 effects 
on local chromatin landscape prevent PRC2 recruitment.  
B) m
6
A-mediated mechanism in which RNA-mediated 
inhibition of PRC2 is dependent on m
6
A methylations  
C) Loss of METTL3 in either mechanism would lead to PRC2 
binding to chromatin, H3K27 trimethylation, and silencing of 
gene expression. 
Limitations of the Present Findings, and Future Experiments 
It is important to acknowledge that the present findings are limited in scope, and 
represent only a preliminary characterization of VCM3 and VCA5 mice, with 
mechanistic studies forthcoming.  
First and foremost, many of the findings are limited by the small sample number. 
This is admittedly due to the difficult nature of fetal liver characterization. This process 
relies on time mating and analysis two weeks later. We are therefore dependent on the 
yield of desirable genotypes within any given litter, and with a probability of only 12.5% 
in our crossings, knockout mice are infrequent. Many of the observed trends in our 
phenotypic data will likely attain significance with increased numbers.  
Mechanistically, it will be important to quantify the m6A content of these 
knockout mice by liquid-chromatography/mass-spectrometry to verify that altered m6A 
levels are caused by deletion of these genes. In the case of the VCM3 mice, several 
studies have demonstrated that knockdown or knockout of METTL3 induces dramtic 
reductions in m6A. The floxed METTL3 construct in these mice is the same that was used 
in the previously published characterization of CD4 T cells, and Vav is a well-
characterized promoter that mediates efficient Cre expression in hematopoietic tissues. 
We therefore expect efficient deletion and altered m6A levels. In ALKBH5 knockout 
mice, there is only a mild increase in total m6A content. Furthermore, alterations in m6A 
levels in VCA5 may be transient or context-dependent, and may be more difficult to 
detect. We will also demonstrate that the observed phenotypes can be reversed by rescue 
of METTL3 and ALKBH5 expression. We will also have to demonstrate that rescue by 
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METTL3 and ALKBH5 is dependent on their m6A-specific function by performing 
rescue with catalytically inactive mutants.     
Beyond these core experiments, we will also have to explore the causal alterations 
in the epitranscriptome, and translational efficiency that are mediated by METTL3 and 
ALKBH5 knockout, as outlined in the aims of this project. As discussed at length 
previously, large cell numbers will be required for miCLIP and ribosomal profiling. To 
this end we will consider performing these studies on whole fetal liver, or on the Lin-
cKit+ fractions. 
Lastly, as evidence continues to emerge regarding the role of METTL3 in 
hematopoiesis, it will be important to demonstrate novel mechanisms and identify novel 
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